var title_f0_16_256="Communicating hydrocele";
var content_f0_16_256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Communicating hydrocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A narrowly patent processus vaginalis that only permits passage of peritoneal fluid results in a communicating hydrocele.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Paidas, C. Inguinal hernia. In: Oski's Pediatrics. Principles and Practice, 3rd ed, McMillan, JA, DeAngelis, CD, Feigin, RD, et al (Eds), Lippincott Williams &amp;Wilkins, Philadelphia 1999. p.1640.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_256=[""].join("\n");
var outline_f0_16_256=null;
var title_f0_16_257="Abd and inguinal intertrigo";
var content_f0_16_257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe intertrigo of the abdominal and inguinal folds in an elderly patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtsey of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_257=[""].join("\n");
var outline_f0_16_257=null;
var title_f0_16_258="Fasciolopsiasis adult worm";
var content_f0_16_258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Fasciolopsiasis adult worm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Adult fluke of",
"    <em>",
"     F. buski",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Fasciolopsiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Fasciolopsiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Fasciolopsiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_258=[""].join("\n");
var outline_f0_16_258=null;
var title_f0_16_259="Eosinophilic fasciitis biopsy 2";
var content_f0_16_259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This high power view of a hematoxylin and eosin stained skin biopsy from a patient with eosinophilic fasciitis shows marked accumulation of eosinophils in close proximity to collagen bundles in the fascia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Varga, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_259=[""].join("\n");
var outline_f0_16_259=null;
var title_f0_16_260="Folic acid, cyanocobalamin, and pyridoxine: Patient drug information";
var content_f0_16_260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Folic acid, cyanocobalamin, and pyridoxine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32403?source=see_link\">",
"     see \"Folic acid, cyanocobalamin, and pyridoxine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      FaBB;",
"     </li>",
"     <li>",
"      Folastin;",
"     </li>",
"     <li>",
"      Folbee&reg;;",
"     </li>",
"     <li>",
"      Folbic&trade;;",
"     </li>",
"     <li>",
"      Folcaps&trade;;",
"     </li>",
"     <li>",
"      Folgard RX&reg;;",
"     </li>",
"     <li>",
"      Folgard&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      Folplex 2.2;",
"     </li>",
"     <li>",
"      Foltabs&trade; 800 [OTC];",
"     </li>",
"     <li>",
"      Foltx&reg; [DSC];",
"     </li>",
"     <li>",
"      Homocysteine Guard [OTC];",
"     </li>",
"     <li>",
"      Lev-Tov [OTC];",
"     </li>",
"     <li>",
"      Tri-B&reg; [OTC];",
"     </li>",
"     <li>",
"      Tricardio B;",
"     </li>",
"     <li>",
"      Virt-Vite Forte;",
"     </li>",
"     <li>",
"      Vita-Respa&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702157",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to folic acid, cyanocobalamin, pyridoxine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11020 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_260=[""].join("\n");
var outline_f0_16_260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019390\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019392\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019391\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019396\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019397\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019399\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019394\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019395\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019400\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019401\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32403?source=related_link\">",
"      Folic acid, cyanocobalamin, and pyridoxine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_261="Atrial fibrillation";
var content_f0_16_261=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Atrial fibrillation (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/16/261/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/261/contributors\" id=\"au4322\">",
"       Leonard I Ganz, MD, FHRS, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/16/261/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/261/contributors\" id=\"se6340\">",
"       Bradley P Knight, MD, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/16/261/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/261/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?0/16/261?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ATRIAL FIBRILLATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Atrial fibrillation (also called AF or a-fib) is an abnormal rhythm of the heart. It is relatively common, affecting 2.3 million adults in the United States. Most people who develop atrial fibrillation are over 65 years of age. Atrial fibrillation is more frequent in men than women, and in whites than blacks.",
"    </p>",
"    <p>",
"     There are two forms of this abnormal heart rhythm:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Intermittent (paroxysmal) atrial fibrillation, which is characterized by episodes that occur with varying frequency and last for a variable period of time before spontaneously stopping.",
"      </li>",
"      <li>",
"       Chronic or persistent atrial fibrillation, which is sustained and does not usually stop spontaneously.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The purpose of this review is to describe the symptoms of atrial fibrillation, its risks, and to review current treatments.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS ATRIAL FIBRILLATION?",
"     </span>",
"    </p>",
"    <p>",
"     In atrial fibrillation, part of the heart (the upper chambers, or atria) does not work correctly because of abnormal electrical activity. This means that blood is not forcefully moved out of these chambers. The blood that remains in the atria becomes \"sluggish\" or static, which allows blood clots to form (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Risk of stroke'",
"     </a>",
"     below). Atrial fibrillation can be intermittent and stop on its own (paroxysmal), continue for several days and require treatment (persistent), or be present all the time (permanent).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ATRIAL FIBRILLATION CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Atrial fibrillation increases in frequency with aging and typically occurs in people who have underlying heart disease. Almost any heart disease can increase the risk of this abnormal rhythm, but the most common causes are:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hypertensive heart disease due to chronic high blood pressure.",
"      </li>",
"      <li>",
"       A heart attack (myocardial infarction, or MI)",
"      </li>",
"      <li>",
"       Heart failure",
"      </li>",
"      <li>",
"       Heart valve disease, such as mitral regurgitation or mitral stenosis. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"        \"Patient information: Mitral regurgitation (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       After heart surgery and, less often, after other types of surgery",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Atrial fibrillation can also be seen with other medical problems. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Alcohol and binge drinking &mdash; Binge drinkers can develop atrial fibrillation that is usually transient. This often occurs over weekends or holidays when alcohol intake is excessive. It is called \"holiday heart syndrome.\"",
"      </li>",
"      <li>",
"       Hyperthyroidism &mdash; Atrial fibrillation occurs in about 13 percent of all people with an overactive thyroid gland (called hyperthyroidism). It has been estimated that hyperthyroidism accounts for 5 percent of cases of atrial fibrillation. Thus, blood testing for this disorder is recommended in anyone with AF since hyperthyroidism is treatable. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"        \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Medications &mdash; Drugs that stimulate the heart can contribute to the development of atrial fibrillation. These include theophylline (used in the treatment of asthma or chronic lung disease) and caffeine.",
"      </li>",
"      <li>",
"       Sleep apnea &mdash; Atrial fibrillation can be caused by sleep apnea, a condition where patients stop breathing for prolonged periods of time while sleeping. Patients with atrial fibrillation who are overweight, or have a history of snoring or excessive sleepiness during the daytime, should be evaluated with a sleep study. Treatment for sleep apnea can eliminate atrial fibrillation in some patients. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"        \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A variety of chronic lung diseases, particularly emphysema.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some people with atrial fibrillation have no apparent cause. When this occurs in people under age 60 to &nbsp;risk of blood clots is much lower than it is in people who are older or who have known causes of atrial fibrillation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ATRIAL FIBRILLATION SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Some people have no symptoms at all while others have a variety of symptoms. Mild symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Unpleasant palpitations or irregularity of the heart beat",
"      </li>",
"      <li>",
"       Mild chest discomfort (sensation of tightness) or pain",
"      </li>",
"      <li>",
"       A sense of the heart racing",
"      </li>",
"      <li>",
"       Lightheadedness",
"      </li>",
"      <li>",
"       Mild shortness of breath and fatigue that limit the ability to exercise",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some patients report severe symptoms:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty breathing",
"      </li>",
"      <li>",
"       Shortness of breath with exertion",
"      </li>",
"      <li>",
"       Fainting, or near fainting, due to a reduction in blood flow to the brain",
"      </li>",
"      <li>",
"       Confusion, due to a reduction in blood supply to the brain",
"      </li>",
"      <li>",
"       Chest discomfort",
"      </li>",
"      <li>",
"       Fatigue",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Chest discomfort generally results from inadequate blood flow to meet the needs of the heart (called angina); this can be due to an increase in the heart's need for oxygen",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a decrease in the heart's supply of blood and oxygen. In some cases, chest pain is due to the rapid heart rate itself or perhaps due to stretching of the heart's chambers. Chest discomfort can also result from worsening heart failure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Risk of stroke",
"     </span>",
"     &nbsp;&mdash;&nbsp;A serious complication associated with atrial fibrillation is stroke, which can lead to permanent brain damage. A stroke can occur if a blood clot forms in the left atrium because of sluggish blood flow and a piece of the clot (called an embolus) breaks off. The embolus enters the blood circulation and can block a small blood vessel. If this happens in the brain, a stroke can occur. The embolus may also travel to the eye, kidneys, spine, or important arteries of the arms or legs. When the symptoms of a stroke resolve completely within 24 hours, it is called a transient ischemic attack (TIA); many patients refer to this as a &ldquo;mini-stroke.&rdquo; (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .) Like atrial fibrillation, the risk of stroke increases with age. Without preventive treatment (eg, blood thinners), stroke occurs in approximately 1.3 percent of people with AF who are 50 to 59 years each year and increases gradually to 5 percent each year for people 80 to 89 years. The other risk factors for stroke include diabetes, high blood pressure, congestive heart failure, or prior stroke or embolus.",
"    </p>",
"    <p>",
"     Taking a blood thinner lowers the risk of stroke (see",
"     <a class=\"local\" href=\"#H16\">",
"      'Treatment to prevent blood clots'",
"     </a>",
"     below). Blood thinners used in this setting include warfarin (Coumadin&reg;), aspirin, or a new agent called dabigatran (Pradaxa&reg;).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ATRIAL FIBRILLATION DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Atrial fibrillation is diagnosed with an electrocardiogram (ECG or EKG), which records the heart's electrical activity. Other tests, such as an echocardiogram (ultrasound), may be performed to look for heart failure or heart valve problems. Blood tests may be used to screen for thyroid disorders. Occasionally, sleep studies and lung function tests are sometimes used to look for sleep apnea or underlying lung disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ATRIAL FIBRILLATION TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Electrical cardioversion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electrical cardioversion involves the use of an electrical shock from a cardioverter, delivered by paddles placed on the chest, to \"reset\" the heart rhythm. Urgent cardioversion is usually performed if AF is interfering with heart's ability to supply blood and oxygen to vital organs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"      \"Patient information: Cardioversion (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some people with newly diagnosed AF can undergo electrical or medical cardioversion (using an antiarrhythmic drug) immediately. However, due to the risk of stroke from blood clots lodged in the left atrium, many people are advised to delay cardioversion until starting treatment with a blood thinner. This medication, (usually warfarin [Coumadin&reg;]) is given for three to four weeks, which allows most preexisting blood clots in the left atrium to resolve.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Transesophageal echocardiogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;Use of a procedure called transesophageal echocardiogram (TEE) is an alternative to delaying cardioversion while starting a blood thinner. The TEE avoids the need for delaying cardioversion until three to four weeks after starting warfarin, but it is still important that the blood is thinned at the time of the cardioversion. The blood can be thinned with either warfarin, or the blood thinner heparin that is administered subcutaneously (under the skin) or intravenously (by vein). A TEE uses a small ultrasound device that is swallowed. The device allows the physician to see the left atrium and look for evidence of blood clots. If there is no evidence of blood clot, cardioversion can be performed safely without three to four weeks of warfarin pretreatment. Although there is still a risk that cardioversion could result in a stroke even when a clot that is not seen on the TEE, the risk is quite small. Following cardioversion, a blood thinner must be continued for at least a month, assuming normal rhythm is maintained.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Long-term treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;For people with intermittent or chronic atrial fibrillation, there are two long-term treatment options: rhythm control and rate control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Rhythm control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rhythm control refers to electrical or medical cardioversion followed by an antiarrhythmic drug to lower the risk of recurrent AF. After successful conversion to normal sinus rhythm, only 20 to 30 percent of people are in sinus rhythm after one year. This can be increased to between 40 and 80 percent by adding an antiarrhythmic drug.",
"    </p>",
"    <p>",
"     The advantages to rhythm control include improved cardiac function and, for some people, reduced symptoms. Selected people who maintain a normal rhythm are allowed to stop blood thinning medications. However, rhythm control is more likely to reduce the frequency of AF than eliminate it entirely. Thus, many people treated with antiarrhythmic medications continue some form of blood thinning medications indefinitely.",
"    </p>",
"    <p>",
"     The disadvantages of rhythm control are the high rate of recurrent AF and side effects associated with antiarrhythmic drugs, including the development of new abnormal heart rhythms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Rate control",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are treated with rate control continue to have AF. However, the person uses a medication (a beta blocker, a calcium channel blocker, or digoxin) to slow conduction through the AV node, thereby keeping the rate of the lower pumping chambers (ventricles) in the normal range. People who use this treatment require treatment with a blood thinner since there is a risk of blood clot formation and possible stroke. (See",
"     <a class=\"local\" href=\"#H16\">",
"      'Treatment to prevent blood clots'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     The major disadvantage of the rate control strategy is sometimes it is difficult to adequately control the rate and relieve symptoms.",
"    </p>",
"    <p>",
"     Either a rate control or a rhythm control strategy, along with a treatment to prevent blood clots, may be appropriate. You should discuss the risks and benefits of each type of treatment with your doctor or nurse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Nonpharmacologic treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are alternate ways to achieve rhythm or rate control, including radiofrequency catheter ablation, use of a pacemaker or implantable atrial defibrillator, and several surgical treatments. &nbsp;(See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Radiofrequency ablation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiofrequency ablation is a procedure that can sometimes cure atrial fibrillation. The technique, however, is still evolving, and there is a small but real risk of serious complications, even with an experienced physician. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"      \"Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Increasingly, this therapy is being considered an initial option in young people who have symptoms of AF who do not wish to take long-term medications. It is also being used increasingly in patients who are having recurrent atrial fibrillation despite using one or more antiarrhythmic drug. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"      \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Surgical procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgical procedures, including the complete maze procedure and the less invasive alternative surgeries, may be considered in some people with AF, especially those who must undergo open-heart surgery for other reasons. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"      \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      TREATMENT TO PREVENT BLOOD CLOTS",
"     </span>",
"    </p>",
"    <p>",
"     People with atrial fibrillation have an increased risk of stroke as a result of blood clots that can form in the heart. As a result, most people are advised to use a treatment to reduce the risk of developing blood clots. The most commonly used treatments include anticoagulants (also called blood thinners) or antiplatelet drugs (such as aspirin).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Anticoagulant drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Taking an anticoagulant (blood thinner) can reduce the risk of having a stroke by approximately 50 to 70 percent. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Warfarin is an anticoagulant that has been used for many years, but a major problem with it is that it increases the risk of bleeding. The most serious type of bleeding is bleeding into the brain. However, the benefit of preventing strokes is greater than the small risk of bleeding into the brain in most cases. If you take warfarin, you will need careful monitoring with periodic blood tests to be sure you are taking the right dose of warfarin.",
"    </p>",
"    <p>",
"     Dabigatran, apixaban, and rivaroxaban are newer anticoagulants that work as well as warfarin, and are as safe, but don&rsquo;t require periodic blood tests. Patients should discuss with their doctors whether one of these newer agents is better for them than warfarin. Further information about dabigatran is available at the following website:",
"     <a class=\"external\" href=\"file://circ.ahajournals.org/content/124/8/e209.full\">",
"      file://circ.ahajournals.org/content/124/8/e209.full",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Antiplatelet drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants are the most effective treatment for preventing blood clots in patients at high-risk of stroke. However, treatment with antiplatelet drugs is a reasonable option in certain people. Aspirin is the most frequently used of this kind.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H191\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394522\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/54/13154?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=see_link\">",
"      Patient information: Tachycardia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=see_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/45/11986?source=see_link\">",
"      Patient information: Supraventricular tachycardia (SVT) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=see_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5394530\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"      Patient information: Cardioversion (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=see_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Harvard Center for Cancer Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.yourdiseaserisk.harvard.edu/\">",
"      www.yourdiseaserisk.harvard.edu/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Includes a calculator for estimating the risk of stroke",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart Rhythm Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hrsonline.org/\">",
"      www.hrsonline.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?0/16/261/abstract/1-8\">",
"      1-8",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 20, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?0/16/261?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/1\">",
"      Silverman DI, Manning WJ. Strategies for cardioversion of atrial fibrillation--time for a change? N Engl J Med 2001; 344:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/2\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/3\">",
"      Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/4\">",
"      van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/5\">",
"      Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/6\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/7\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/261/abstract/8\">",
"      Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f0_16_261=[""].join("\n");
var outline_f0_16_261=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ATRIAL FIBRILLATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS ATRIAL FIBRILLATION?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ATRIAL FIBRILLATION CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ATRIAL FIBRILLATION SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ATRIAL FIBRILLATION DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ATRIAL FIBRILLATION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           TREATMENT TO PREVENT BLOOD CLOTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_262="Basic principles of electrocardiographic interpretation";
var content_f0_16_262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic principles of electrocardiographic interpretation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/262/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/262/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/262/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/262/contributors\">",
"     David M Mirvis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/262/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/262/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/16/262/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is a graphical record of electric potentials generated by the heart muscle during each cardiac cycle. These potentials are detected on the surface of the body using electrodes attached to the extremities and chest wall, and are then amplified by the electrocardiograph machine and displayed on special graph paper.",
"   </p>",
"   <p>",
"    This topic will review the basic aspects of ECG interpretation, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The cardiac electrical cycle",
"     </li>",
"     <li>",
"      ECG waveforms and intervals",
"     </li>",
"     <li>",
"      ECG leads",
"     </li>",
"     <li>",
"      Genesis of the normal ECG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these issues is discussed in greater detail in published reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/262/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE CARDIAC ELECTRICAL CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiating event for cardiac contraction is the spread of depolarizing electrical currents through the heart. These currents are produced by three types of cells: cardiac pacemaker cells; specialized conduction tissue; and the heart muscle itself. The surface ECG, however, only records the depolarization and repolarization potentials generated by the \"working\" atrial and ventricular myocardial fibers.",
"   </p>",
"   <p>",
"    The depolarization stimulus for the heartbeat normally begins in the sinoatrial (SA) or sinus node, a collection of pacemaker cells with spontaneous automaticity (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6614?source=see_link\">",
"     \"Anatomy and electrophysiology of the sinoatrial node\"",
"    </a>",
"    .) The initial phase of cardiac electrical activation consists of the spread of the depolarization wave through the right and left atria, resulting in atrial contraction. As the impulse reaches the base of the intraatrial septum, it also stimulates pacemaker and specialized conduction tissues in the atrioventricular (AV) nodal and His-bundle areas. Together, these two regions constitute the AV junction.",
"   </p>",
"   <p>",
"    The bundle of His splits into two main branches, the right and the left bundles. The main left bundle bifurcates into two primary subdivisions: a left anterior fascicle; and a left posterior fascicle. The bundle branches and fascicles rapidly transmit depolarization wavefronts to the myocardium by way of Purkinje fibers that penetrate the ventricular walls to excite the working ventricular myocardial cells. The depolarization wavefronts spread through the ventricular wall, from endocardium (inner layer) to epicardium (outer layer), triggering intracellular calcium release and myofilament contraction (electromechanical coupling).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ECG ELECTRODES AND LEADS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodes are the sites at which an electrical potential is measured, while ECG leads record the difference in potentials between two electrodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard surface electrodes (right and left arm, right and left leg, and the six precordial electrodes) measure the electrical potential at a site.",
"   </p>",
"   <p>",
"    In addition, a reference site, the central terminal of Wilson, is calculated from the average voltage of the limb leads. This idealized site is meant to represent a reference at the center of Einthoven's triangle where total current is zero. The central terminal is referred to as the reference or indifferent electrode. Unipolar ECG leads are derived from the difference between the measured voltage at a surface electrode and the calculated voltage at this central reference point.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ECG leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 12 conventional ECG leads record differences in electrical potentials, either between two surface electrodes (bipolar leads), or between a surface electrode and the central terminal of Wilson (unipolar leads).",
"   </p>",
"   <p>",
"    ECG leads are divided into two groups: six extremity (limb) leads and six chest (precordial) leads. The extremity leads record potentials transmitted onto the frontal plane and the chest leads record potentials transmitted onto the horizontal plane (",
"    <a class=\"graphic graphic_figure graphicRef65700 \" href=\"UTD.htm?17/31/17904\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Limb leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six extremity, or limb, leads are further subdivided into three bipolar leads (I, II and III) and three unipolar leads (aVR, aVL and aVF). Each bipolar lead measures the difference in potential between electrodes at two extremities, with one electrode connected to the positive pole and the other to the negative pole of the voltmeter:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lead I records the difference between potential sensed by the electrode placed on the left arm (the positive pole) and one placed on the right arm (negative pole).",
"     </li>",
"     <li>",
"      Lead II records the difference between electrodes on the left leg (positive) and the right arm (negative).",
"     </li>",
"     <li>",
"      Lead III records the difference between electrodes on the left leg (positive) and the left arm (negative).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These were the leads of the original string galvanometer, the forerunner of the modern electrocardiograph introduced by the Dutch physiologist, Dr. Willem Einthoven at the beginning of the 20th century.",
"   </p>",
"   <p>",
"    The \"unipolar\" limb leads, in comparison, measure the cardiac voltage (V) at one site relative to the central terminal, which has approximately zero potential. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lead aVR records right arm potentials",
"     </li>",
"     <li>",
"      Lead aVL records left arm potentials",
"     </li>",
"     <li>",
"      Lead aVF records left leg (foot) potentials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower case \"a\" indicates that these potentials are augmented by 50 percent. The right leg electrode functions as a ground.",
"   </p>",
"   <p>",
"    The spatial orientation and polarity of the six frontal plane leads is represented on the hexaxial diagram (",
"    <a class=\"graphic graphic_figure graphicRef65292 \" href=\"UTD.htm?27/60/28622\">",
"     figure 3",
"    </a>",
"    ). As examples, lead I is primarily a left-right lead, while aVF is an inferior-superior lead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Precordial leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six chest, or precordial, leads are also unipolar recordings. They represent the voltage difference between the central terminal and electrodes placed in the following positions (",
"    <a class=\"graphic graphic_figure graphicRef75588 \" href=\"UTD.htm?6/48/6912\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      V1 &mdash; 4th intercostal space (ICS), just to the right of the sternum",
"     </li>",
"     <li>",
"      V2 &mdash; 4th ICS, just to the left of the sternum",
"     </li>",
"     <li>",
"      V3 &mdash; midway between V2 and V4",
"     </li>",
"     <li>",
"      V4 &mdash; 5th ICS in the mid-clavicular line",
"     </li>",
"     <li>",
"      V5 &mdash; anterior axillary line, same level as V4",
"     </li>",
"     <li>",
"      V6 &mdash; mid-axillary line, same level as V4 and V5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inadvertent misplacement of chest leads is quite common and can lead to considerable diagnostic confusion.",
"   </p>",
"   <p>",
"    The ECG leads are designed so that a positive (upright) deflection will be recorded in a lead if a wave of depolarization spreads toward the positive pole of that lead. A negative deflection will be recorded if the wave of depolarization spreads toward the negative pole of any lead (ie, away from the positive role). As an example, depolarization spreading to the left and posterior will produce a positive deflection in lead I (a left-right lead) and a negative deflection in lead V1 (an anterior-posterior lead). If, however, the mean orientation of the depolarization vector (or electrical axis) is at right angles to a given lead axis, a small biphasic (equally positive and negative) deflection will be recorded.",
"   </p>",
"   <p>",
"    Together, the frontal and horizontal plane electrodes provide a three-dimensional report of cardiac electrical activity. Each lead can be likened to a different video camera angle \"looking\" at the same dynamic events &mdash; atrial and ventricular depolarization and repolarization &mdash; from different spatial orientations. The standard 12 lead ECG can be supplemented with additional leads under special circumstances. For example, right precordial leads, such as V3R and V4R are useful in detecting acute right ventricular ischemia or infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ECG WAVEFORMS AND INTERVALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG waves are labeled alphabetically starting with the P wave which represents atrial depolarization (",
"    <a class=\"graphic graphic_figure graphicRef76390 \" href=\"UTD.htm?30/21/31069\">",
"     figure 5",
"    </a>",
"    ). The QRS complex represents ventricular depolarization and the ST-T-U complex (ST segment, T wave and U wave) represents ventricular repolarization. The J point is the junction between the end of the QRS and beginning of the ST segment. (Atrial repolarization occurs during the PR segment and QRS complex but is usually of too low an amplitude to be detected, but may become apparent in conditions such as acute pericarditis or atrial infarction.)",
"   </p>",
"   <p>",
"    The QRS-T waveforms on the surface ECG correspond in a general way to the different phases of simultaneously obtained ventricular action potentials, the intracellular recordings from single myocardial fibers (",
"    <a class=\"graphic graphic_figure graphicRef78354 \" href=\"UTD.htm?33/3/33852\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QRS onset corresponds to the rapid upstroke (phase 0) of the action potential.",
"     </li>",
"     <li>",
"      The isoelectric ST segment corresponds to phase 2 of the action potential (plateau phase), during which myocardial fibers normally achieve about the same potential.",
"     </li>",
"     <li>",
"      The T wave corresponds to phase 3 of the action potential (active repolarization).",
"     </li>",
"     <li>",
"      The isoelectric segment between the end of the T wave and the next depolarization corresponds to phase 4 of the action potential (recovery).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that decrease the slope of phase 0 by, for example, impairing the influx of sodium tend to increase QRS duration (eg, severe hyperkalemia or drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    ). On the other hand, factors that prolong phase 2 (eg, hypocalcemia or drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ) increase the QT interval. In contrast, factors such as digitalis and hypercalcemia shorten ventricular repolarization (phase 2) and abbreviate the ST segment.",
"   </p>",
"   <p>",
"    The ECG waves are recorded on special graph paper which is divided into 1 mm",
"    <sup>",
"     2",
"    </sup>",
"    grid-like boxes. The ECG paper speed is ordinarily 25",
"    <span class=\"nowrap\">",
"     mm/sec.",
"    </span>",
"    As a result, each 1 mm horizontal box corresponds to 0.04 second (40 ms), with heavier lines at larger 0.20 sec (200 ms) intervals. Vertically, the ECG graph measures the height (amplitude) of a given wave or deflection, as 10 mm equals 1 mV with standard calibration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ECG intervals",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major ECG intervals: R-R (inversely related to the heart rate), PR, QRS, and",
"    <span class=\"nowrap\">",
"     QT/QTc",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef76390 \" href=\"UTD.htm?30/21/31069\">",
"     figure 5",
"    </a>",
"    ). The heart rate",
"    <span class=\"nowrap\">",
"     (beats/min)",
"    </span>",
"    can be readily computed from the interbeat (R-R) interval by dividing the number of large (0.20 sec) time units between consecutive R waves into 300 or, for more precise measurement, the number of small (0.04 sec) units into 1500.",
"   </p>",
"   <p>",
"    The PR interval measures the time (normally 0.12 to 0.20 sec; 3 to 5 small boxes) between the onset of atrial and ventricular depolarization. This includes the physiologic delay imposed by stimulation of cells in the AV junction area.",
"   </p>",
"   <p>",
"    The QRS interval (normally &le;0.10 sec; 2",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    small boxes) is a measure of the duration of ventricular depolarization. The QRS complex is subdivided into specific deflections or waves. If the initial QRS deflection in a given lead is negative, it is termed a Q wave. The first positive deflection is termed an R wave. A negative deflection after an R wave is called an S wave. Subsequent positive or negative waves are labeled R' or S', respectively. Lower case letters (q, r, or s) are used for relatively small amplitude waves of less than 0.5 mV (less than 5 mm with standard calibration). An entirely negative QRS complex is called a QS wave.",
"   </p>",
"   <p>",
"    The QT interval begins with the onset of the QRS complex and ends at the end of the T-wave, subtends both ventricular depolarization and repolarization times, and varies inversely with the heart rate. A rate-related (or corrected) QT interval (QTc) can be calculated from:",
"   </p>",
"   <p>",
"    &nbsp;QTc &nbsp; = &nbsp; QT interval &nbsp;&divide; &nbsp;square root of the RR interval",
"   </p>",
"   <p>",
"    The upper limit of the normal value for the QTc is approximately 0.44.",
"   </p>",
"   <p>",
"    A number of other formulas have also been suggested for correcting the QT for heart rate. However, there is no consensus on an optimal way to do this correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENESIS OF THE NORMAL ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direction and magnitude of the ECG waveform reflects the sequential vectors of atrial and ventricular depolarization and repolarization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     P wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wave of atrial depolarization normally travels downward and toward the subject's left, reflecting the spread of the depolarization stimulus from the sinus node to the right and left atrial muscle and the AV junction. This downward and left vector points toward the positive pole of lead II and the negative pole of lead aVR (",
"    <a class=\"graphic graphic_figure graphicRef55410 \" href=\"UTD.htm?43/12/44224\">",
"     figure 7",
"    </a>",
"    ). As a result, the normal sinus P wave is positive (upright) in lead II and negative (downward) in lead aVR. In contrast, activation of the atria from an ectopic pacemaker in the lower part of either atrium or in the AV junction region may produce retrograde P waves moving upward and to the right. This will produce P waves that are negative in lead II and positive in lead aVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     QRS complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal ventricular depolarization can be divided into two major, sequential phases. Each phase can be represented by a mean vector (",
"    <a class=\"graphic graphic_figure graphicRef63074 \" href=\"UTD.htm?42/14/43247\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first phase is depolarization of the interventricular septum from left to right (vector 1).",
"     </li>",
"     <li>",
"      The second phase is simultaneous depolarization of the main mass of the right and left ventricles. This second phase is normally dominated by the more massive left ventricle so that vector 2 points leftward and posteriorly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a right precordial lead like V1 will record this biphasic depolarization process with a small positive deflection (septal r wave) followed by a larger negative deflection (S wave). In contrast, a left precordial lead such as V6 will record the same sequence with a small negative deflection (septal q wave) followed by a relatively tall positive deflection (R wave). Intermediate precordial leads show a relative increase in R wave amplitude and a decrease in S wave amplitude progressing across the chest from right to left (",
"    <a class=\"graphic graphic_waveform graphicRef58149 \" href=\"UTD.htm?36/55/37751\">",
"     waveform 1",
"    </a>",
"    ). This normal R wave progression in the precordial leads is a reflection of the progressively more leftward orientation of these leads. The precordial lead where the R wave and S wave are of about equal amplitude is referred to as the transition zone (usually lead V3 or V4).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     QRS axis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrical axis describes the overall orientation of the QRS vector with reference to the six frontal plane leads. The QRS pattern in the extremity leads may vary considerably from one normal subject to another depending upon the electrical axis of the QRS complex.",
"   </p>",
"   <p>",
"    The normal QRS axis in adults ranges from about -30&ordm; to + 100&ordm; (",
"    <a class=\"graphic graphic_figure graphicRef65292 \" href=\"UTD.htm?27/60/28622\">",
"     figure 3",
"    </a>",
"    ). An axis more negative than -30&ordm; is referred to as left axis deviation (LAD), while an axis more positive than +100&ordm; is referred to as right axis deviation (RAD).",
"   </p>",
"   <p>",
"    Left axis deviation can occur as a normal variant, but is most commonly associated with a more pronounced leftward QRS vector due to left ventricular hypertrophy, a block in the anterior fascicle of the left bundle system (left anterior fascicular block or hemiblock) or inferior myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16886?source=see_link\">",
"     \"Left anterior fascicular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Right axis deviation can also occur as a normal variant (particularly in children and young adults), as a spurious finding due to reversal of the left and right arm electrodes, or in such conditions such as right ventricular overload syndromes (acute or chronic), apicolateral wall infarction of the left ventricle, dextrocardia, left pneumothorax, or left posterior fascicular block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=see_link\">",
"     \"Left posterior fascicular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The QRS axis can be estimated as being at right angles to the positive pole of any extremity lead in which the positive and negative deflections are of roughly equal magnitude. With lead II, for example, the positive pole is at +60&ordm; (",
"    <a class=\"graphic graphic_figure graphicRef65292 \" href=\"UTD.htm?27/60/28622\">",
"     figure 3",
"    </a>",
"    ); as a result, the axis must be either -30&ordm; (borderline LAD) or +150&ordm; (RAD) if the QRS complex has positive and negative waves of roughly equal magnitude in that lead. These two possibilities can be readily distinguished by looking at another lead such as lead I (positive pole at +0&ordm;), which will be have a net positive deflection with LAD and negative deflection with RAD.",
"   </p>",
"   <p>",
"    In general, you can usually determine whether the QRS electrical axis is normal, leftward or rightward from simple inspection of leads I and II (",
"    <a class=\"graphic graphic_figure graphicRef57151 \" href=\"UTD.htm?42/10/43182\">",
"     figure 9",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal QRS axis: Net QRS area positive in I and II.",
"     </li>",
"     <li>",
"      Left axis deviation: Net QRS positive in I, negative in II.",
"     </li>",
"     <li>",
"      Right axis deviation: Net QRS negative in I, positive in II.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     T and U waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal ECG, the orientation of the mean T wave vector is roughly the same as the mean QRS vector. Since depolarization and repolarization are electrically opposite processes, this physiologic QRS-T wave vector concordance indicates that repolarization must normally proceed in the reverse direction from depolarization (ie, from epicardium to endocardium or from cardiac apex to base).",
"   </p>",
"   <p>",
"    The normal U wave is a small rounded deflection (&le;1 mm) following the T wave, which usually has the same polarity of the T wave. An abnormal increase in U wave amplitude is most commonly due to drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ) or hypokalemia. Very prominent U waves with prolonged ventricular repolarization (long QT interval) are associated with increased susceptibility to torsades de pointes, a type of polymorphic ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9241824\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The electrocardiogram (ECG) is a graphical record that sums the electric potentials generated by the heart muscle during each cardiac cycle. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The conventional ECG is recorded using 12 leads, applied to the arms, legs, and chest, that represent the difference in electrical potentials in the frontal and horizontal planes of the body. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'ECG electrodes and leads'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECG waves are labeled alphabetically starting with the P wave, which represents atrial depolarization. The QRS complex represents ventricular depolarization and the ST-T-U complex (ST segment, T wave and U wave) represents ventricular repolarization. The J point is the junction between the end of the QRS and beginning of the ST segment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'ECG waveforms and intervals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four major ECG intervals: R-R (inversely related to the heart rate), PR, QRS, and",
"      <span class=\"nowrap\">",
"       QT/QTc.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'ECG waveforms and intervals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ECG can be conceptualized in terms of vectors (arrows with magnitude and direction) that represent the orientation and balance of cardiac depolarization and repolarization forces projected onto the ECG leads. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Genesis of the normal ECG'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goldberger, AL, Goldberger, E. Clinical Electrocardiography: A Simplified Approach, 7th ed, Elsevier/Mosby, Inc, St. Louis 2006.",
"    </li>",
"    <li>",
"     Mirvis, DM, Goldberger, AL. Electrocardiography. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9th ed, Bonow, RO, Mann, DL, Zipes, DP, Libby, P (Eds), W.B. Saunders Company, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/262/abstract/3\">",
"      Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram. Part I: The electrocardiogram and its technology. A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Heart Rhythm 2007; 4:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2098 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9D0B6BF364-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_262=[""].join("\n");
var outline_f0_16_262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9241824\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE CARDIAC ELECTRICAL CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ECG ELECTRODES AND LEADS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Electrodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ECG leads",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Limb leads",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Precordial leads",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ECG WAVEFORMS AND INTERVALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ECG intervals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENESIS OF THE NORMAL ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      P wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      QRS complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      QRS axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T and U waves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9241824\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2098|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/52/43841\" title=\"figure 1\">",
"      Normal conduction system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17904\" title=\"figure 2\">",
"      Activity of ECG leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/60/28622\" title=\"figure 3\">",
"      Electrical axis of ECG leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/48/6912\" title=\"figure 4\">",
"      Placement of precordial leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/21/31069\" title=\"figure 5\">",
"      Generation of ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/3/33852\" title=\"figure 6\">",
"      ECG and action potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/12/44224\" title=\"figure 7\">",
"      Generation of the P wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43247\" title=\"figure 8\">",
"      Generation of the QRS complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/10/43182\" title=\"figure 9\">",
"      Left and right axis deviation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2098|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/55/37751\" title=\"waveform 1\">",
"      ECG of sinus rhythm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6614?source=related_link\">",
"      Anatomy and electrophysiology of the sinoatrial node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16886?source=related_link\">",
"      Left anterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=related_link\">",
"      Left posterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_263="Dehydroepiandrosterone and its sulfate";
var content_f0_16_263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dehydroepiandrosterone and its sulfate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/263/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/263/contributors\">",
"     George P Chrousos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/263/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/263/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/263/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/263/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/16/263/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal production of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA sulfate or DHEA-S) is substantial in both men and women. The production of both is greatest among young adults, and it declines progressively with age. At their peak at age 25 years, serum DHEA concentrations range from 0.2 to 0.9",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (7 to 31",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    10-fold lower than those of cortisol, and serum DHEA-S concentrations range from 75 to 370",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2 to 10",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    20-fold higher than those of cortisol. By age 80 years, the concentrations are only about 20 percent of those at age 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DHEA is converted to DHEA-S in the adrenal and liver, both of which contain a sulfotransferase. The former is produced from the latter in peripheral tissues that contain a sulfatase. In the adrenal glands and peripheral tissues such as hair follicles, prostate, external genitalia, and adipose tissue, small amounts of DHEA and DHEA-S are converted to more active androgens such as androstenedione, androstenediol, testosterone, and 5-dihydrotestosterone, and estrogens such as estradiol and estrone. These hormones then exert their usual androgenic and estrogenic effects via the androgen and estrogen receptors, respectively. In women, adrenal production of DHEA and DHEA-S contributes substantially to overall androgen production and effects; in men the adrenal contribution is very small.",
"   </p>",
"   <p>",
"    DHEA has been proposed to have many actions, including vasodilatory, anti-aging, anti-inflammatory, anti-atherosclerotic actions and anti-depressant, and it is widely available in stores that sell health foods and nutritional supplements. However, quality control of these products has been shown to be quite poor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible sites of action and clinical uses of DHEA are reviewed here. Measurements of adrenal androgens and the causes and effects of excess endogenous production of DHEA and DHEA-S are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=see_link\">",
"     \"Measurement of adrenal androgens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSSIBLE SITES OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA and DHEA-S act, after conversion to androgens and estrogens, by activating androgen and estrogen receptors, respectively, as noted above.",
"   </p>",
"   <p>",
"    In addition, there are five receptors other than the androgen and estrogen receptor with which DHEA and DHEA-S may interact in vitro, but the clinical importance of these interactions is not known. They are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gamma-aminobutyric acid",
"      <span class=\"nowrap\">",
"       (GABA)-A/benzodiazepine",
"      </span>",
"      receptor complex, via which DHEA and DHEA-S may antagonize the effects of GABA [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      N-methyl-aspartate excitatory amino acid receptors, where DHEA may potentiate the effects of glutamate [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A novel nuclear hormone-type receptor called CAR, for which reduced metabolites of DHEA may be the natural ligands [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A cell-surface receptor in vascular endothelial cells that binds DHEA (but not DHEA-S) and is functionally coupled to G-proteins and nitric oxide synthase [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The sigma-1 receptor binds neurosteroids, including DHEA and DHEA-S, which have antidepressant-like effects in animal models of depression [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     USE IN ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, the adrenal cortex is the primary source of androgen in the form of DHEA and DHEA-S. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    .) DHEA and DHEA-S production is low in patients with primary or secondary adrenal insufficiency, resulting in androgen deficiency, particularly in women. The physiological role of these androgens in women is not known, and replacement of them has not historically been part of the treatment regimen for patients with adrenal insufficiency. Clinical trial data suggest that androgen replacement therapy (DHEA) in women with primary or secondary adrenal insufficiency may be beneficial.",
"   </p>",
"   <p>",
"    In the United States, the use of DHEA is severely limited by the lack of product quality control, as DHEA is considered to be a diet supplement rather than a hormone preparation. Therefore, DHEA supplements available commercially may not actually contain the advertised dose. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of adrenal androgen replacement has been evaluated in several studies of patients with adrenal insufficiency:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 24 women with primary adrenal insufficiency who were receiving adequate glucocorticoid and mineralocorticoid therapy, administration of DHEA in a dose of 50 mg daily for four months increased serum androgen concentrations into the normal range [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/11\">",
"       11",
"      </a>",
"      ]. General and psychological well-being and sexuality increased, and scores on tests of depression and anxiety were lower after treatment with DHEA as compared with placebo. Most of the women had only transient, mild, skin-related androgenic side effects, but five had more pronounced effects.",
"      <br/>",
"      <br/>",
"      In the same study, DHEA replacement had no effect on carbohydrate metabolism, body composition, or exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second, randomized, double-blind study of 15 men and 24 women with primary adrenal insufficiency, DHEA (50 mg daily) improved self-esteem and overall sense of well-being in both sexes, with less fatigue and improved mood in the evening [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/13\">",
"       13",
"      </a>",
"      ]. The beneficial effects in men suggest that DHEA may act directly on the brain.",
"     </li>",
"     <li>",
"      Results were somewhat different in a 12-month trial in 106 men and women with primary adrenal insufficiency. DHEA (50",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      prevented bone loss at the femoral neck (but not other sites), and increased total body and truncal lean body mass with no change in fat mass. There was no significant benefit of DHEA on fatigue, cognitive function, or sexual function, and only minimal effect on psychological well-being [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher doses of DHEA (200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      did not appear to cause more severe side effects, but provided no additional clinical benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Doses lower than 50 mg may not be effective. In a nine-month study of 39 women with adrenal insufficiency, 25 mg DHEA was no more effective than placebo in increasing well-being and sexuality, and 89 percent of the women given DHEA had side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DHEA (50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 12 weeks) improved insulin sensitivity (as measured by hyperinsulinemic-euglycemic clamp studies in a placebo-controlled trial) in 28 women with primary adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/17\">",
"       17",
"      </a>",
"      ]. DHEA also reduced serum total cholesterol, triglyceride, and LDL concentrations, however, HDL concentrations decreased as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower doses of DHEA may be effective in women with ACTH deficiency (secondary adrenal insufficiency). In a study of 38 women with hypopituitarism, administration of DHEA (20 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six months) resulted in increases in serum androgens, axillary and pubic hair, and energy, but no increase in sexual interest or activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/18\">",
"     18",
"    </a>",
"    ]. In a second trial of DHEA in men and women with panhypopituitarism (ACTH and gonadotropin deficiency), modest and minor improvements were seen in psychological well-being in the women and men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a published placebo-controlled double blind study of adolescent girls with central adrenal insufficiency, daily replacement with 25mg DHEA orally was beneficial: atrichia pubis vanished, and psychological well-being improved significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other effects of DHEA in patients with adrenal insufficiency and a meta-analysis of its efficacy for depression and quality of life are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Androgen replacement (DHEA)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OTHER PROPOSED USES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Athletic performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA has been given to trained athletes in an attempt to improve performance. The effect of DHEA on muscle strength is unclear as results from clinical trials have been conflicting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of androgens and other hormones to enhance athletic performance\", section on 'Androgen precursors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with systemic lupus erythematosus (SLE) have low serum DHEA and DHEA-S concentrations, even prior to initiating chronic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/21\">",
"     21",
"    </a>",
"    ]. The possible beneficial and adverse effects of DHEA when used in patients with SLE are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fibromyalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA appears to be ineffective for the treatment of fibromyalgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=see_link\">",
"     \"Initial treatment of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease manifestations in primary Sj&ouml;gren's syndrome are associated with low sex hormone levels: dry mouth symptoms with low androgens and dry eyes with low estrogens. In a double blind placebo-controlled study, oral exogenous DHEA at the dose of",
"    <span class=\"nowrap\">",
"     50mg/day",
"    </span>",
"    was preferentially transformed into androgens rather than estrogens and its administration was associated with some improvement of dry mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA may also be more effective than placebo for the treatment of depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H35#H35\">",
"     \"Initial treatment of depression in adults\", section on 'DHEA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Perimenopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA does not appear to be effective for perimenopausal symptoms. This was illustrated in a trial of 60 symptomatic perimenopausal women in whom DHEA 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    when compared to placebo, did not result in significantly greater improvements in the severity of perimenopausal symptoms, mood, dysphoria, libido, cognition, memory, or well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anti-aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;It had been thought that DHEA might have antiaging effects, with possible beneficial effects on well-being, cognitive function, and body compositions. However, most data suggest that this is not the case.",
"   </p>",
"   <p>",
"    In postmenopausal women and older men, in whom serum DHEA and DHEA-S concentrations are considerably lower than in younger subjects, administration of DHEA in doses of 50 to 100 mg daily for 3 to 24 months raises serum DHEA and DHEA-S concentrations to values comparable to those in young subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/24-30\">",
"     24-30",
"    </a>",
"    ]. Small increases in serum testosterone and estradiol have also been observed in women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/29\">",
"     29",
"    </a>",
"    ]. Although physiologic serum concentrations of DHEA may be achieved, the clinical benefits observed are inconsistent as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial of aging women and men, DHEA improved psychological well-being [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/24\">",
"       24",
"      </a>",
"      ]. However, most trials have not seen improvements in sense of well-being on quality-of-life measures with DHEA administration [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/26,27,29\">",
"       26,27,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DHEA has had no effect on either muscle size or strength in most trials of elderly subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of DHEA reduces visceral fat accumulation in obese rats and mice [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/32\">",
"       32",
"      </a>",
"      ]. In humans, the effects of DHEA on body composition have been inconsistent. One small trial reported a significant decrease in abdominal visceral and subcutaneous fat [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/33\">",
"       33",
"      </a>",
"      ], but others [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/27,28,31,34\">",
"       27,28,31,34",
"      </a>",
"      ], including two larger, longer-term trials [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/29,30\">",
"       29,30",
"      </a>",
"      ], have reported no effect of DHEA [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/27-31,34\">",
"       27-31,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One small trial reported an improvement in insulin sensitivity with DHEA therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/33\">",
"       33",
"      </a>",
"      ], but a larger, longer-term study did not [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are somewhat limited, DHEA replacement improved bone mineral density in elderly subjects with low serum DHEA concentrations in some [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/25,34\">",
"     25,34",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/26\">",
"     26",
"    </a>",
"    ], studies. In the largest trial, 140 older men and women were randomly assigned to DHEA 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or placebo for 12 months. DHEA increased bone density significantly more than placebo at the hip, and in women, the lumbar spine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/34\">",
"     34",
"    </a>",
"    ]. Similar results were noted in a two-year trial [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the improvements in bone density reported are very small when compared with those seen with approved drugs for osteoporosis. In the absence of fracture data, the clinical significance of these findings is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In elderly individuals with established dementia, DHEA therapy does not appear to improve cognitive performance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/35\">",
"     35",
"    </a>",
"    ]. A systematic review of the literature concluded that DHEA replacement does not appear to improve memory or other aspects of cognitive function in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vaginal atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravaginal DHEA administration may be a novel therapy for postmenopausal women with atrophic vaginitis and sexual dysfunction. In a trial of postmenopausal women with symptomatic vaginal atrophy, 12 weeks of intravaginal DHEA administration corrected signs and symptoms of atrophy and, when compared with placebo, appeared to improve some measures of sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. No significant increases in serum DHEA or estrogen concentrations were seen. Further study is necessary to know if this will be a safe and effective therapy. This agent is not commercially available. Other treatments for vaginal atrophy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women taking DHEA may achieve serum DHEA concentrations in the supraphysiologic range [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/23,26,33\">",
"     23,26,33",
"    </a>",
"    ], and increases in serum testosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/29\">",
"     29",
"    </a>",
"    ], raising concerns about long-term metabolic. Most studies report androgenic side effects including oily skin, hirsutism, and acne.",
"   </p>",
"   <p>",
"    Other adverse effects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower serum HDL cholesterol concentrations in most [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/23,24,27\">",
"       23,24,27",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/28\">",
"       28",
"      </a>",
"      ] trials.",
"     </li>",
"     <li>",
"      DHEA replacement has been associated with cases of mania and palpitations [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although serious adverse effects have not been reported, the long-term safety of DHEA therapy has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Androgen replacement (DHEA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, most data suggest that DHEA replacement in older men and women does not have a significant effect on psychological well-being, body composition, muscle strength, or insulin sensitivity. While there may be improvements in bone density, the changes are very small and of uncertain clinical importance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA has been proposed to have many actions, including vasodilatory, anti-aging, anti-inflammatory, anti-atherosclerotic, and anti-depressant actions. However, the clinical benefits and safety of DHEA for a number of clinical conditions is not well established. While DHEA is available by prescription only in most countries, in the United States, DHEA is widely available in stores that sell health foods and nutritional supplements. However, quality control (purity and potency) of these over-the-counter products has been shown to be quite poor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/263/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest DHEA therapy only in women with adrenal insufficiency with impaired mood or sense of well-being despite optimal glucocorticoid and, if needed, mineralocorticoid replacement. However, this approach is limited by the lack of reliable source of this compound in some countries (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Its role in men with adrenal insufficiency is not well-established. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Use in adrenal insufficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of adrenal insufficiency in adults\", section on 'Androgen replacement (DHEA)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest not using DHEA for other indications, including athletic performance enhancement, treatment of SLE, Sj&ouml;gren&rsquo;s syndrome depression, or as androgen replacement in otherwise healthy postmenopausal women and elderly individuals (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other proposed uses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preliminary studies, locally administered intra-vaginal DHEA at low doses may be effective for vaginal dryness. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vaginal atrophy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/1\">",
"      Nippoldt TB, Nair KS. Is there a case for DHEA replacement? Baillieres Clin Endocrinol Metab 1998; 12:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/2\">",
"      Oelkers W. Dehydroepiandrosterone for adrenal insufficiency. N Engl J Med 1999; 341:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/3\">",
"      Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999; 39:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/4\">",
"      Parasrampuria J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA 1998; 280:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/5\">",
"      Thompson RD, Carlson M, Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int 2000; 83:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/6\">",
"      Sousa A, Ticku MK. Interactions of the neurosteroid dehydroepiandrosterone sulfate with the GABA(A) receptor complex reveals that it may act via the picrotoxin site. J Pharmacol Exp Ther 1997; 282:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/7\">",
"      Johansson T, Le Grev&egrave;s P. The effect of dehydroepiandrosterone sulfate and allopregnanolone sulfate on the binding of [(3)H]ifenprodil to the N-methyl-d-aspartate receptor in rat frontal cortex membrane. J Steroid Biochem Mol Biol 2005; 94:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/8\">",
"      Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998; 395:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/9\">",
"      Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 2002; 277:21379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/10\">",
"      Takebayashi M, Hayashi T, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 2004; 37 Suppl 3:S208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/11\">",
"      Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/12\">",
"      Callies F, Fassnacht M, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 2001; 86:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/13\">",
"      Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000; 85:4650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/14\">",
"      Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 2008; 93:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/15\">",
"      Gebre-Medhin G, Husebye ES, Mallmin H, et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol (Oxf) 2000; 52:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/16\">",
"      L&oslash;v&aring;s K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003; 88:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/17\">",
"      Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005; 54:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/18\">",
"      Johannsson G, Burman P, Wir&eacute;n L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 2002; 87:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/19\">",
"      Brooke AM, Kalingag LA, Miraki-Moud F, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 2006; 91:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/20\">",
"      Rice SP, Agarwal N, Bolusani H, et al. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab 2009; 94:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/21\">",
"      Suzuki T, Suzuki N, Engleman EG, et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 99:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/22\">",
"      Forsblad-d'Elia H, Carlsten H, Labrie F, et al. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab 2009; 94:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/23\">",
"      Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999; 84:3896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/24\">",
"      Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/25\">",
"      Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997; 82:3498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/26\">",
"      Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/27\">",
"      Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab 1999; 84:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/28\">",
"      Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001; 86:4686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/29\">",
"      Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/30\">",
"      Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000; 97:4279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/31\">",
"      Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 2003; 163:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/32\">",
"      Apostolova G, Schweizer RA, Balazs Z, et al. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 2005; 288:E957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/33\">",
"      Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004; 292:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/34\">",
"      Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 2006; 91:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/35\">",
"      Wolkowitz OM, Kramer JH, Reus VI, et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 2003; 60:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/36\">",
"      Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function . Cochrane Database Syst Rev 2001; :CD000304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/37\">",
"      Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009; 16:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/38\">",
"      Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009; 16:907.",
"     </a>",
"    </li>",
"    <li>",
"     The Medical Letter May 9, 2005; 47:37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/263/abstract/40\">",
"      Sahelian R, Borken S. Dehydroepiandrosterone and cardiac arrhythmia. Ann Intern Med 1998; 129:588.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 129 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_263=[""].join("\n");
var outline_f0_16_263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSSIBLE SITES OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      USE IN ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OTHER PROPOSED USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Athletic performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Perimenopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anti-aging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14586?source=related_link\">",
"      Initial treatment of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=related_link\">",
"      Measurement of adrenal androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=related_link\">",
"      Use of androgens and other hormones to enhance athletic performance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_264="Technical aspects of nocturnal hemodialysis";
var content_f0_16_264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Technical aspects of nocturnal hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/264/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/264/contributors\">",
"     Andreas Pierratos, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/264/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/264/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/16/264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate of patients undergoing maintenance hemodialysis is unacceptably high [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/1\">",
"     1",
"    </a>",
"    ]. An extremely high morbidity, relatively low quality of life (due in part to a high level of dependence and unemployment), and high cost of care have also been observed.",
"   </p>",
"   <p>",
"    Instituting more intensive dialysis regimens appears to improve morbidity and possible mortality in this patient population. Compared to conventional three times per week regimens, for example, dialysis associated with longer duration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    higher frequency correlates with enhanced outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. However, the HEMO study found that increasing the dialysis dose within the general restrictions of a thrice weekly regimen failed to decrease patient mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these findings, nocturnal hemodialysis (eg, long nightly home hemodialysis) was introduced as a (possibly) more desirable alternative to conventional dialysis, since it provides superior dialysis based upon dose, duration, and frequency. This can be accomplished because it is performed during nightly sleep, an otherwise unproductive time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Sheldon is credited for overnight dialysis at home [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/12\">",
"     12",
"    </a>",
"    ], Uldall started the first quotidian (daily) nocturnal hemodialysis program in 1994 in Toronto [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Since then, its use has been extended to more centers in Canada, the United States, Australia, and several European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A description of nocturnal hemodialysis, particularly the exact regimen associated with the procedure, will be presented here. Outcomes associated with nocturnal hemodialysis and an overview of short daily hemodialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=see_link\">",
"     \"Outcomes associated with nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIALYSIS REGIMEN AND PRESCRIPTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541554921\">",
"    <span class=\"h2\">",
"     Regimen schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal hemodialysis is performed either at home or in a dialysis facility. When it is done at home, the frequency of dialysis varies from three to seven nights per week. Facility-based nocturnal hemodialysis is performed three nights per week [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Required personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facility-based dialysis is usually performed by the facility staff. Home dialysis is performed by the patient or a helper (unpaid or paid). A partner is",
"    <strong>",
"     NOT",
"    </strong>",
"    absolutely required for nocturnal dialysis at home since this procedure is associated with significant hemodynamic stability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal hemodialysis is performed during sleep for a variable amount of time (usually 6 to more than 10 hours) depending upon the length of sleep desired. For facility-based dialysis, the duration of the dialysis session is generally also dictated by facility logistics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dialysate composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical composition of the dialysate is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium &mdash; 140",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Potassium &mdash; 2",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Bicarbonate &mdash; 30",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      for nightly regimen and 35 mEq for every other night or thrice weekly regimens",
"     </li>",
"     <li>",
"      Calcium &mdash; 2.5 to 4",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (1.25 to 2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      with average of 3.2",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (1.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      The dialysate calcium concentration is adjusted to keep parathyroid hormone levels in the desirable range while maintaining normal predialysis calcium concentrations. This may require the postdialysis serum calcium to be often in the hypercalcemic range. The dialysate calcium concentration can be adjusted by varying the amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=see_link\">",
"       calcium chloride",
"      </a>",
"      powder added to the dialysate by the patient (eg, 7 mL of calcium chloride powder added to 4 L of acid dialysate concentrate increases calcium concentration by approximately 0.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [0.25",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"      <br/>",
"      <br/>",
"      A higher dialysate calcium is prescribed in patients with high ultrafiltration volumes (see below). Such patients are more likely to be in negative calcium balance since the ultrafiltrate contains ionized calcium; thus, the larger the volume removed, the more calcium is lost [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/19\">",
"       19",
"      </a>",
"      ]. Pregnancy or hungry bone syndrome also requires higher levels of dialysate calcium [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=see_link\">",
"       \"Hungry bone syndrome following parathyroidectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phosphate &mdash; 0 to 4.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0 to 1.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      typically 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       Sodium phosphate",
"      </a>",
"      (in the form of Fleet enema) is added, if needed, into the acid or bicarbonate concentrate. The dialysate phosphate concentration is adjusted to maintain pre- and postdialysis phosphate concentrations within the normal range. The typical dose of Fleet enema is 30 to 60 mL per dialysate concentrate jug, but amounts as high as 200 mL can be used as a source of phosphate for those with higher requirements such as pregnant patients or those with hungry bone syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Calcium and phosphate do not precipitate in the presence of the acidic pH of the acid concentrate [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/22\">",
"       22",
"      </a>",
"      ]. Patients on intermittent nocturnal hemodialysis are less likely to need phosphate additive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood and dialysate flow rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since blood flow as low as or below 200",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    is adequate for most patients undergoing nocturnal hemodialysis, a poorly functioning dialysis catheter and a single-needle system (when using a fistula or graft) can provide adequate flow. A single needle system provides extra safety, as accidental disconnection can trigger an air detector alarm. A typical blood flow is 200 to 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Lower flows can be used in children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/23\">",
"     23",
"    </a>",
"    ], although higher flows can be used as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dialysate flow rate is also variable. This can range from 100 to 800",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    A typical regimen is a blood flow rate of 200 to 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a dialysate flow rate of 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical volume of ultrafiltrate removed per day is approximately one to two liters, but larger volumes are well tolerated. Patients weigh themselves daily to maintain dry weight, which is defined as normotension without the need for antihypertensive medications or edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dialyzer membrane and hemodialysis machine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any dialyzer membrane can be used, including smaller surface area dialyzers. Although there are no published data, most centers use high flux dialyzers. In addition, nocturnal hemodialysis can be performed with any hemodialysis machine. Existing machines have been modified and new machines have been designed for use at home [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. In the case of the NxStage machine, the usual dialysate volume is 20 to 25 L [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/29\">",
"     29",
"    </a>",
"    ]. Using this volume for nocturnal hemodialysis may not increase the removal of small molecules but phosphate and large molecule removal increases. In addition, higher dialysate volume enhances small molecule clearance. Attractive attributes of a home dialysis machine include ease of operation, low noise, easily accessible screen that dims at night, back-up battery to protect from power failure, easy disinfection process, and easy single needle system use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dialyzer reuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed dialyzer reprocessing has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. With this technique, dialyzer membranes are rinsed with heparinized saline after dialysis and subsequently stored in a small refrigerator at home. Once a week, these membranes are transported to the center and exchanged with a set of the patient's own reprocessed dialyzers. Most of the centers use new dialyzers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To maintain systemic anticoagulation, the standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimen is the administration of approximately 1000 units of heparin per hour.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/18/41254?source=see_link\">",
"     Danaparoid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     Argatroban",
"    </a>",
"    have also been used successfully in the case of heparin allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both central venous catheters and peripheral vascular accesses have been successfully used for nocturnal hemodialysis. When peripheral accesses are used however, more frequent access cannulation may result in decreased access survival. This was suggested by the Frequent Hemodialysis Network (FHN) Daily and Nocturnal trials, in which the primary vascular outcome was time to first access event (including repair, loss of access or access-related hospitalization), and the secondary vascular outcome was the time to all repairs and time to all losses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the FHN Nocturnal trial 87 participants were randomly assigned to receive in-center six days per week hemodialysis or conventional three days per week hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/35\">",
"     35",
"    </a>",
"    ]. Compared with conventional dialysis, there was a non-significant trend toward a higher rate of first access events associated with nocturnal dialysis (32 versus 58 events per 100 patient years, respectively, hazard ratio [HR] 1.81, 95% CI 0.94&ndash;3.48). When patients with a tunneled catheter were excluded from the analysis, nocturnal dialysis was associated with a significantly increased risk of a first access event (HR 3.23, 95% CI 1.07&ndash;10.34). In the FHN Daily trial, (n = 245 participants), there was a higher incidence of a first access event in the daily group compared with the conventional group. The FHN Daily trial is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link&amp;anchor=H26#H26\">",
"     \"Short daily hemodialysis\", section on 'Vascular access'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any type of central venous catheter can be used for nocturnal hemodialysis. The capability of the catheter to provide blood flow of more than 200",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    is not important for most patients. A safe connection for the central catheter includes the use of pre-perforated catheter caps, which are not removed during dialysis. The InterLink (Becton-Dickinson, Utah, USA), the TEGO (ICU Medical, CA, USA), and the Swan-Lock (Codan, Lensahn, Germany) systems have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/11,36,37\">",
"     11,36,37",
"    </a>",
"    ]. Careful taping of the catheter-tubing connection is of paramount importance. Accidental disconnection of the venous limb can cause exsanguination without triggering machine alarms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H541554937\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombosis &mdash; The local instillation of 2 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (tissue-type plasminogen activator or tPA) has been very successful in restoring adequate blood flow in thrombosed catheters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link&amp;anchor=H79683300#H79683300\">",
"       \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Catheter malfunction'",
"      </a>",
"      .) The instillation of lyophilized tPA has been practiced successfully by patients at home.",
"      <br/>",
"      <br/>",
"      The approach to the prevention of catheter thrombosis is variable in different centers. The prophylactic use of tPA has been advocated to prevent catheter thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/38\">",
"       38",
"      </a>",
"      ]. Most patients in our center use a small dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to prevent catheter thrombosis. The initial dose is usually 2",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      For patients with recurrent thrombosis, the warfarin dose is increased by 1 mg until patency is maintained, providing the INR remains below the levels that the physician considers safe (usually INR below 2). [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/11,39\">",
"       11,39",
"      </a>",
"      ]. A prospective randomized controlled study did not find the use of low dose warfarin useful in preventing catheter dysfunction however [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/40\">",
"       40",
"      </a>",
"      ]. The risk of bleeding, vascular calcification related to the use of warfarin, and the negative trial cited should be considered for individual patients.",
"     </li>",
"     <li>",
"      Infection &mdash; The incidence of catheter-induced bacteremias with nocturnal hemodialysis is relatively low (approximately 0.35 to",
"      <span class=\"nowrap\">",
"       1.5/1000",
"      </span>",
"      days) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/36\">",
"       36",
"      </a>",
"      ]. At our center, patients with fever and chills during the initiation of dialysis but without severe symptoms, such as hypotension, usually draw blood cultures at home and begin empiric treatment with intravenous antibiotics (usually 1 gm of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      and 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       Tobramycin",
"      </a>",
"      if they have previously tolerated such agents). The treatment is subsequently modified based upon culture results and continues for two weeks. If appropriate based upon culture results, continuation of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      rather than Vancomycin is encouraged. If the infection recurs (in our experience usually one month later), the catheter is replaced over a guidewire after restarting or continuing antibiotic coverage. A different site should be chosen if an exit site is present.",
"      <br/>",
"      <br/>",
"      Many bacteremias resolve successfully with antibiotics. We immediately remove the catheter with severe sepsis especially if associated with hemodynamic instability or suspicion of metastatic infection. The infection rate and survival of the catheters on nocturnal hemodialysis may be better than conventional hemodialysis, but data from randomized controlled studies are absent [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/36,41\">",
"       36,41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This approach differs somewhat from that presented elsewhere within UpToDate, relating to the management of conventionally dialyzed patients with possibly infected hemodialysis catheters. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"       \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Arteriovenous fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arteriovenous (AV) fistula is the access of choice. The standard steel needles, blunt needles, and plastic cannulas have been used successfully. The buttonhole technique, which involves the insertion of the",
"    <span class=\"nowrap\">",
"     needle/cannula",
"    </span>",
"    through exactly the same hole and at the same angle and depth of penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/42-45\">",
"     42-45",
"    </a>",
"    ] is used by most patients. After 8 to 10 cannulations (or 12 to 14 in diabetic patients) using the buttonhole method, an epithelialized track develops that allows the use of blunt needles [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/44\">",
"     44",
"    </a>",
"    ]. Sharp needles should be used for the first week, followed by &ldquo;blunt&rdquo; needles thereafter. Before cannulation, the fistula and surrounding skin are cleansed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    (0.5 percent in 70 percent alcohol) or povidone-iodine solution. Scabs are covered with an alcohol pad for five minutes and then removed using a sterile needle.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     Mupirocin",
"    </a>",
"    calcium 2 percent cream (Bactroban, Glaxo-Smith-Klein) is applied to each buttonhole with a sterile cotton swab after hemostasis is achieved and allowed to air dry. A single application is provided for each HD procedure. Mupirocin prophylaxis appears to significantly lower the risk of staphylococcus aureus bacteremia with buttonhole cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Buttonhole cannulation without the use of local",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    can be associated with staphylococcus aureus bacteremia often leading to life threatening metastatic infections. The risk of infection was examined in a randomized trial of 140 conventional hemodialysis patients assigned to either the buttonhole technique or to conventional &ldquo;rope ladder&rdquo; needling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/46\">",
"     46",
"    </a>",
"    ]. At eight weeks, the rate of localized infection was higher among patients assigned to the buttonhole technique compared with conventional needling (50 versus 22.4 per 1000, respectively). There was one episode of staphylococcus aureus bacteremia at eight weeks and two more episodes after the study ended, but within twelve months, in the group utilizing the buttonhole technique versus none in the conventional needling group. At twelve months, the number of needling site abscesses requiring intravenous antibiotics was higher in the buttonhole group versus the conventional needling group (9 versus 0, respectively). The degree to which these data from conventional hemodialysis patients may be extrapolated to nocturnal daily hemodialysis or self-cannulating patients is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of the increased risk of infection, avoidance of buttonhole cannulation has been advocated by some experts. We have not seen any case of staphylococcus aureus bacteremia in our center since the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    use started a number of years ago. Most centers do not practice the buttonhole technique for facility based dialysis.",
"   </p>",
"   <p>",
"    The buttonhole technique may be associated with fewer thrombotic complications among patients undergoing nocturnal or daily dialysis. In the FHN trial, compared with the rope-ladder technique, the buttonhole technique was associated with longer intervals between access-related events (HR 0.44, 95% CI 0.20-0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/35\">",
"     35",
"    </a>",
"    ]. This benefit was driven mostly by a reduction in thrombotic episodes. Irrespective of technique (ie, buttonhole versus rope ladder), more frequent cannulation may lead to more frequent access-related complications. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Access'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To ensure the safety of the procedure, adequate taping of the needle and anchoring of the blood tubing are essential; enuresis pads wrapped around the connection are also considered essential [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/48\">",
"     48",
"    </a>",
"    ]. Blood leaks trigger an audible alarm. Dedicated disposable leak sensors are available (RedSense Medical AB) as well as non-disposable wireless leak sensors that stop the blood pump when triggered (Fresenius Medical Care, Waltham, MA). No case of accidental disconnection has been reported.",
"   </p>",
"   <p>",
"    The single needle system provides adequate blood flow (average 200",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    while providing extra safety in case of accidental disconnection by triggering an air detection alarm. Thus, it may be the access system of choice for nocturnal hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Arteriovenous grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous (AV) grafts have been successful. The buttonhole technique is not practiced with these accesses. A different hole is used with every dialysis following the conventional technique. Steel needles or plastic cannulas can be used. Preference should be given to the single needle technique to minimize the number of punctures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Remote monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers practice live remote monitoring of patients at home via either regular telephone lines or the Internet [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. All the information available on the dialysis machine, including conditions that trigger alarms, is available to an observer at the center. The patient who is not awakened by the alarm is called.",
"   </p>",
"   <p>",
"    Live monitoring provides the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Helps prevent blood from clotting in an idle extracorporeal system",
"     </li>",
"     <li>",
"      Provides reassurance to the patient",
"     </li>",
"     <li>",
"      Ensures compliance",
"     </li>",
"     <li>",
"      Aides the collection of data",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these benefits, such monitoring has not yet detected life-threatening conditions. Thus, its use should be considered optional [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/24\">",
"     24",
"    </a>",
"    ]. Most centers do not practice remote monitoring of patients on nocturnal hemodialysis although some centers use remote monitoring for selected patients or for short periods of time (three months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Additional safety measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two inexpensive moisture sensors are placed strategically on the floor to detect dialysate and blood leaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION AND TRAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients capable of performing home hemodialysis or those with home helpers are eligible for nocturnal hemodialysis. Exclusion criteria include acute illnesses, uncontrolled seizure activity, and contraindication to systemic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/24\">",
"     24",
"    </a>",
"    ]. The presence of older age, an unstable cardiovascular system, hypotension, diabetes mellitus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascites are all indications, and not contraindications, for nocturnal hemodialysis. An aid to facilitate the home dialysis choice for patients has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient groups that can be preferentially targeted for nocturnal hemodialysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incident patients followed in a chronic kidney disease (CKD) clinic. To prevent the state of dependence frequently encountered in in-center dialysis units, training should be instituted early or patients should be dialyzed temporarily in self-care settings.",
"     </li>",
"     <li>",
"      Patients ineligible for kidney transplantation. Nocturnal hemodialysis can be viewed as the dialysis modality closest to kidney transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with significant morbidity, including cardiac disease, diabetes mellitus, severe hypertension, dialysis-related symptoms, or large intradialytic weight gains.",
"     </li>",
"     <li>",
"      Patients who require conversion from peritoneal dialysis to hemodialysis and who want to maintain independence.",
"     </li>",
"     <li>",
"      Large-size patients or patients not adequately dialyzed because of poor access flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The length of training depends upon the patient's previous experience. The typical duration for a previously untrained patient is six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/53\">",
"     53",
"    </a>",
"    ]. During the first five weeks, patients are dialyzed on conventional or short daily hemodialysis. Although not mandatory, patients generally sleep in the training facility while on nocturnal hemodialysis during the last one to three nights. Training includes drawing blood samples for laboratory tests and blood cultures, as well as self-administering intravenous medications including antibiotics and iron preparations. Supplies at home include test tubes, a centrifuge, blood culture bottles, antibiotics, and in selected cases lyophilized rTPA.",
"   </p>",
"   <p>",
"    The adoption of nocturnal hemodialysis may be hampered by patient-perceived barriers, including lack of confidence in their ability to perform necessary duties (eg, self-cannulation), fear of a possible catastrophic event, and the reluctance to burden family members [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/264/abstract/54\">",
"     54",
"    </a>",
"    ]. Financial barriers can be significant. Costs include increased home utility fees for the patients and low dialysis reimbursement rates especially when more than thrice weekly dialysis is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocturnal hemodialysis can be practiced in the facility (thrice weekly) or at home (three to seven nights per week). Home nocturnal hemodialysis is performed either by the patient or partner (a partner not being absolutely required) during sleep for a variable amount of time, based upon the length of sleep desired (usually 6 to 10 hours in total). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Required personnel'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with conventional hemodialysis and depending on the frequency the dialysate contains lower levels of bicarbonate, higher levels of calcium, and often contains phosphate. Typical flow rates are a blood flow rate of 200 to 300",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and a dialysate flow rate of 300",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      The typical volume of ultrafiltrate removed per day is approximately 1 to 2 liters but higher volumes are well tolerated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dialysate composition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Ultrafiltration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Blood and dialysate flow rates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To maintain systemic anticoagulation, the standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      regimen is the administration of approximately 1000 units of heparin per hour. Central venous catheters, arteriovenous fistulas, and arteriovenous grafts have been successfully used for nocturnal hemodialysis. Safety devices are important to prevent accidental access disconnection and bleeding during sleep. An arteriovenous (AV) fistula is the preferred vascular access using a single needle system. The use of the &lsquo;buttonhole&rsquo; technique offers advantages, but is associated with high rate of systemic infections by staphylococcus aureus. Local application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"       mupirocin",
"      </a>",
"      cream at the puncture site appears to decrease or eliminate this risk. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Anticoagulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some centers practice live remote monitoring of patients at home either via regular telephone lines or the Internet, while others do not practice remote monitoring. Its use should be considered optional. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Remote monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients capable of performing home hemodialysis are eligible for nocturnal hemodialysis. Exceptions include acute illnesses, uncontrolled seizures, and contraindication to systemic anticoagulation. Significant comorbidities can be indications rather than contraindications for nocturnal hemodialysis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patient selection and training'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Morbidity and mortality. In: United States Renal Data System, Vol 2: 2010 Annual Data Report in the United States, file://www.usrds.org/2010/slides/indiv/1v2index.html file://www.usrds.org/adr.htm (Accessed on July 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/2\">",
"      Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/3\">",
"      Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/4\">",
"      Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 1998; 13 Suppl 6:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/5\">",
"      Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting \"daily\" hemodialysis. Kidney Int 1999; 55:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/6\">",
"      Locatelli F, Buoncristiani U, Canaud B, et al. Dialysis dose and frequency. Nephrol Dial Transplant 2005; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/7\">",
"      Kjellstrand C, Buoncristiani U, Ting G, et al. Survival with short-daily hemodialysis: association of time, site, and dose of dialysis. Hemodial Int 2010; 14:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/8\">",
"      Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/9\">",
"      Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/10\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/11\">",
"      Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/12\">",
"      Shaldon S. Independence in maintenance haemodialysis. Lancet 1968; 1:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/13\">",
"      Udall, PR, Francoeur, R, Ouwendyk, M. Simplified nocturnal home hemodialysis (SNHHD). A new approach to renal replacement therapy. J Am Soc Nephrol 1994; 5:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/14\">",
"      Lindsay RM, Daily/Nocturnal Dialysis Study Group. The London, Ontario, Daily/Nocturnal Hemodialysis Study. Semin Dial 2004; 17:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/15\">",
"      Lockridge RS Jr, Spencer M, Craft V, et al. Nocturnal home hemodialysis in North America. Adv Ren Replace Ther 2001; 8:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/16\">",
"      Agar JW, Somerville CA, Dwyer KM, et al. Nocturnal hemodialysis in australia. Hemodial Int 2003; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/17\">",
"      Kooistra MP. Frequent prolonged home haemodialysis: three old concepts, one modern solution. Nephrol Dial Transplant 2003; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/18\">",
"      Lacson E Jr, Wang W, Lester K, et al. Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program. Clin J Am Soc Nephrol 2010; 5:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/19\">",
"      Al-Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003; 14:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/20\">",
"      Barua M, Hladunewich M, Keunen J, et al. Successful pregnancies on nocturnal home hemodialysis. Clin J Am Soc Nephrol 2008; 3:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/21\">",
"      Su WS, Lekas P, Carlisle EJ, et al. Management of hypophosphatemia in nocturnal hemodialysis with phosphate-containing enema: a technical study. Hemodial Int 2011; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/22\">",
"      Ing TS, Yu AW, Agrawal B, et al. Increasing plasma phosphorus values by enriching with phosphorus the \"acid concentrate\" of a bicarbonate-buffered dialysate delivery system. Int J Artif Organs 1992; 15:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/23\">",
"      Geary DF, Piva E, Tyrrell J, et al. Home nocturnal hemodialysis in children. J Pediatr 2005; 147:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/24\">",
"      Pierratos A. Daily nocturnal home hemodialysis. Kidney Int 2004; 65:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/25\">",
"      Kjellstrand CM, Blagg CR, Bower J, Twardowski ZJ. The Aksys personal hemodialysis system. Semin Dial 2004; 17:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/26\">",
"      Ledebo I, Fredin R. The Gambro system for home daily dialysis. Semin Dial 2004; 17:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/27\">",
"      Kelly TD. Baxter Aurora dialysis system. Semin Dial 2004; 17:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/28\">",
"      Schlaeper C, Diaz-Buxo JA. The Fresenius Medical Care home hemodialysis system. Semin Dial 2004; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/29\">",
"      Clark WR, Turk JE Jr. The NxStage System One. Semin Dial 2004; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/30\">",
"      Ash SR. The Allient dialysis system. Semin Dial 2004; 17:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/31\">",
"      Trewin E. Bellco Formula Domus Home Care System. Semin Dial 2004; 17:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/32\">",
"      Pierratos, A, Francoeur, R, Ouwendyk, M. Delayed dialyzer reprocessing for home hemodialysis. Home Hemodial Int 2000; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/33\">",
"      Twardowski ZJ. Dialyzer reuse-Part I: Historical perspective. Semin Dial 2006; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/34\">",
"      Faratro R, D'Gama C, Chan C. The use of alternative anti-coagulation strategies for a nocturnal home hemodialysis patient with heparin-induced thrombocytopenia. CANNT J 2008; 18:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/35\">",
"      Suri RS, Larive B, Sherer S, et al. Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol 2013; 24:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/36\">",
"      Pipkin M, Craft V, Spencer M, Lockridge RS Jr. Six years of experience with nightly home hemodialysis access. Hemodial Int 2004; 8:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/37\">",
"      Eloot S, De Vos JY, Hombrouckx R, Verdonck P. How much is catheter flow influenced by the use of closed luer lock access devices? Nephrol Dial Transplant 2007; 22:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/38\">",
"      Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/39\">",
"      Twardowski, ZJ. Stepwise Anticoagulation with Warfarin for Prevention of Intravenous Catheter Thrombosis. Hemodialysis Int 2000; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/40\">",
"      Wilkieson TJ, Ingram AJ, Crowther MA, et al. Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol 2011; 6:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/41\">",
"      Perl J, Lok CE, Chan CT. Central venous catheter outcomes in nocturnal hemodialysis. Kidney Int 2006; 70:1348.",
"     </a>",
"    </li>",
"    <li>",
"     Twardowski, ZJ, Harper, G. Buttonhole method of needle insertion into arteriovenous fistulas. 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/43\">",
"      Twardowski, Z, Kubara, H. Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis. Dial Transpl 1979; 8:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/44\">",
"      Hashmi A, Cheema MQ, Moss AH. Hemodialysis patients' experience with and attitudes toward the buttonhole technique for arteriovenous fistula cannulation. Clin Nephrol 2010; 74:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/45\">",
"      Nesrallah GE, Cuerden M, Wong JH, Pierratos A. Staphylococcus aureus bacteremia and buttonhole cannulation: long-term safety and efficacy of mupirocin prophylaxis. Clin J Am Soc Nephrol 2010; 5:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/46\">",
"      MacRae JM, Ahmed SB, Atkar R, Hemmelgarn BR. A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/47\">",
"      Zimmerman D, Lok CE. Accessing the access. Clin J Am Soc Nephrol 2012; 7:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/48\">",
"      Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/49\">",
"      Hoy, CD. Remote Monitoring of Daily Nocturnal Hemodialysis. Hemodialysis Int 2001; 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/50\">",
"      Heidenheim AP, Leitch R, Kortas C, et al. Patient monitoring in the London Daily/Nocturnal Hemodialysis Study. Am J Kidney Dis 2003; 42:61.",
"     </a>",
"    </li>",
"    <li>",
"     MATCH-D group. Method to assess treatment choices for home dialysis (MATCH-D). 2011. file://www.homedialysis.org/files/pros/MatchD2009.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/52\">",
"      Pauly RP, Gill JS, Rose CL, et al. Survival among nocturnal home haemodialysis patients compared to kidney transplant recipients. Nephrol Dial Transplant 2009; 24:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/53\">",
"      Leitch R, Ouwendyk M, Ferguson E, et al. Nursing issues related to patient selection, vascular access, and education in quotidian hemodialysis. Am J Kidney Dis 2003; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/264/abstract/54\">",
"      Cafazzo JA, Leonard K, Easty AC, et al. Patient-perceived barriers to the adoption of nocturnal home hemodialysis. Clin J Am Soc Nephrol 2009; 4:784.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1904 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_264=[""].join("\n");
var outline_f0_16_264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIALYSIS REGIMEN AND PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H541554921\">",
"      Regimen schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Required personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dialysate composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood and dialysate flow rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dialyzer membrane and hemodialysis machine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dialyzer reuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H541554937\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Arteriovenous fistulas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Arteriovenous grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Remote monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Additional safety measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PATIENT SELECTION AND TRAINING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=related_link\">",
"      Hungry bone syndrome following parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=related_link\">",
"      Outcomes associated with nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_265="Treatment and prognosis of Guillain-Barr syndrome in adults";
var content_f0_16_265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/265/contributors\">",
"     Francine J Vriesendorp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/265/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/265/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/16/265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barr&eacute; syndrome (GBS), after the authors of early descriptions of the disease. GBS is an acute monophasic paralyzing illness usually provoked by a preceding infection.",
"   </p>",
"   <p>",
"    The treatment and prognosis of GBS in adults will be discussed here. Other aspects of GBS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link\">",
"     \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is extremely important in Guillain-Barr&eacute; syndrome (GBS) since up to 30 percent of patients develop neuromuscular respiratory failure requiring mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, autonomic dysfunction may be severe enough to require intensive care unit (ICU) monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, many patients with GBS are initially admitted to the ICU for close monitoring of respiratory, cardiac, and hemodynamic function. Less severely affected patients can be managed in intermediate care units, and mildly affected patients can be managed on the general ward with telemetry, along with monitoring of blood pressure and vital capacity every four hours.",
"   </p>",
"   <p>",
"    Prophylaxis for deep vein thrombosis, bladder and bowel care, physical and occupational therapy, and psychological support are essential. Subcutaneous fractionated or unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and support stockings are recommended until patients are able to walk independently [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]. Adequate pain control is necessary. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Pain control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Issues related to the respiratory management of patients with neuromuscular weakness are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vigilance is essential when caring for a patient with GBS, since deterioration due to progression of muscle weakness can occur rapidly.",
"   </p>",
"   <p>",
"    Respiratory failure in GBS is common, and 15 to 30 percent of patients need ventilatory support. Thus, close respiratory monitoring with frequent measurement of vital capacity and negative inspiratory force (NIF) should be instituted initially in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]. Bulbar dysfunction with swallowing problems and inability to clear secretions may add to the need for ventilatory support.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    should be avoided when invasive airway management becomes necessary. The techniques and medications for rapid sequence intubation in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following parameters warn of impending respiratory arrest and are an indication for intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forced vital capacity &lt;20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      Maximum inspiratory pressure &lt;30 cmH2O",
"     </li>",
"     <li>",
"      Maximum expiratory pressure &lt;40 cmH2O",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific clinical findings and measurements on admission predict a high risk for respiratory failure. In a French prospective study of 722 patients with GBS not ventilated at admission, mechanical ventilation was needed in 313 (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/4\">",
"     4",
"    </a>",
"    ]. The following factors were identified as predictors of respiratory failure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Time of onset to admission less than seven days",
"     </li>",
"     <li>",
"      Inability to cough",
"     </li>",
"     <li>",
"      Inability to stand",
"     </li>",
"     <li>",
"      Inability to lift the elbows",
"     </li>",
"     <li>",
"      Inability to lift the head",
"     </li>",
"     <li>",
"      Liver enzyme increases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with at least four of these six predictors, mechanical ventilation was required in &gt;85 percent.",
"   </p>",
"   <p>",
"    In the 196 patients whose vital capacity was measured on admission, time from onset to admission of less than seven days, inability to lift the head, and vital capacity &lt;60 percent of normal predicted mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/4\">",
"     4",
"    </a>",
"    ]. In patients with all three of these predictors, mechanical ventilation was required in 85 percent.",
"   </p>",
"   <p>",
"    Weaning from mechanical ventilation should be guided by improvement in strength and serial pulmonary function tests (PFTs) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]. Tracheostomy should be performed after two weeks if PFTs do not show any significant improvement from baseline, but can be deferred for another week if PFTs do show improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic dysfunction is a well-recognized feature of GBS and is a significant source of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/5\">",
"     5",
"    </a>",
"    ]. Dysautonomia occurs in 70 percent of patients and manifests as symptoms that include tachycardia (the most common), urinary retention, hypertension alternating with hypotension, orthostatic hypotension, bradycardia, other arrhythmias, ileus, and loss of sweating.",
"   </p>",
"   <p>",
"    Severe autonomic disturbances occur in about 20 percent of patients, mostly (but not always) in patients who develop severe weakness and respiratory failure.",
"   </p>",
"   <p>",
"    Consequently, close monitoring of blood pressure, fluid status, and cardiac rhythm is essential to the management of patients with GBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiovascular management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In agreement with a 2005 expert review and consensus opinion of supportive care for patients with GBS, we recommend pulse and blood pressure monitoring for patients with GBS who are becoming severely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]. Monitoring should be instituted at time of admission.",
"   </p>",
"   <p>",
"    Monitoring should be continued until ventilatory support is no longer necessary or until recovery is underway in patients not needing mechanical ventilation.",
"   </p>",
"   <p>",
"    Practical tips for the management of patients with GBS include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quadriplegic patients should not be left unattended in the sitting position without assessment of orthostatic hypotension",
"     </li>",
"     <li>",
"      Intravascular volume should be maintained, particularly during positive-pressure ventilation",
"     </li>",
"     <li>",
"      Drugs with hypotensive side effects should be avoided if possible",
"     </li>",
"     <li>",
"      Arrhythmias frequently occur during suctioning",
"     </li>",
"     <li>",
"      Plasma exchange can cause hypotension and electrolyte disturbances",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both paroxysmal hypertension and orthostatic hypotension are frequent, occurring in 24 and 19 percent of patients with GBS, respectively, while sustained hypertension occurs in 3 percent, as described in a series of 169 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraarterial monitoring should be instituted in the presence of significant blood pressure fluctuations. Hypotension can usually be treated with fluids, but low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    can be used if fluids are not effective. In the presence of dysautonomia, only low doses of carefully titrated short-acting vasoactive agents should be used for treatment of hypotension and hypertension because of the potential to overshoot the target blood pressure in the setting of possible denervation hypersensitivity.",
"   </p>",
"   <p>",
"    Episodes of severe hypertension (MAP&gt;125) can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In cases of autonomic cardiovascular dysfunction, other conditions must be excluded, such as pulmonary thromboembolism, hypoxemia, sepsis, gastrointestinal (GI) bleeding, and fluid and electrolyte disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained sinus tachycardia occurs in 37 percent of patients and requires no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe cardiac arrhythmias, including bradycardia and asystole, occur in about 4 percent of patients with GBS. Other arrhythmias and electrocardiogram (EKG) changes have also been described: atrial fibrillation, atrial flutter, paroxysmal tachycardia, ventricular tachycardia, elevated or depressed ST segments, flat or inverted T waves, Q-T interval prolongation, axis deviation, and various conduction blocks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/2\">",
"     2",
"    </a>",
"    ]. Other causes of cardiovascular disease need to be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bowel and bladder care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional autonomic problems include adynamic ileus and urinary retention. Daily abdominal auscultation to monitor for bowel silence and the development of adynamic ileus is recommended, as is monitoring of opioid administration.",
"   </p>",
"   <p>",
"    For treating ileus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"     neostigmine",
"    </a>",
"    may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic pain occurs in about 40 to 50 percent of patients during the course of GBS and often requires treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    may be used for intensive care unit pain control during the acute phase of GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. Simple analgesics or nonsteroidal antiinflammatory drugs (NSAIDS) may be tried, but they often do not provide adequate pain relief. Appropriate narcotic analgesics may be used but require careful monitoring for adverse effects in the setting of autonomic denervation. Epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    also can be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the long-term management of neuropathic pain, tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute-phase rehabilitation should include an individualized program of gentle strengthening, involving isometric, isotonic, isokinetic, and manual resistive and progressive resistive exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]. Rehabilitation should emphasize proper limb positioning, posture, and orthotics as well as nutrition. A device to help with communication may be necessary.",
"   </p>",
"   <p>",
"    After the acute phase, disabled patients should be treated by a multidisciplinary rehabilitation team [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/10\">",
"     10",
"    </a>",
"    ]. An exercise program may be beneficial for persistent fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISEASE MODIFYING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main modalities of therapy for Guillain-Barr&eacute; syndrome (GBS) include plasma exchange (also called plasmapheresis) and administration of intravenous immune globulin (IVIG).",
"   </p>",
"   <p>",
"    Plasmapheresis is thought to remove circulating antibodies, complement, and soluble biological response modifiers.",
"   </p>",
"   <p>",
"    The precise mechanism of action for intravenous immune globulin (IVIG) in GBS is unknown but may include providing anti-idiotypic antibodies, modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, and interfering with activation and effector functions of T and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The roles of the immune response, molecular mimicry, and antiganglioside antibodies in the pathogenesis of GBS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large, randomized multicenter trials have established the effectiveness of plasma exchange in patients with severe GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Earlier improvement in muscle strength, reduced need for mechanical ventilation, and better recovery have been demonstrated.",
"   </p>",
"   <p>",
"    In an updated (2012) meta-analysis of six randomized controlled trials and 649 patients with GBS, treatment with plasma exchange was superior to supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median time to recover walking with aid was shorter in the plasma exchange group than the control group in two trials that reported this primary outcome measure.",
"     </li>",
"     <li>",
"      The time to onset of motor recovery in mildly affected patients was significantly shorter in the plasma exchange group in the one trial that reported this primary outcome measure.",
"     </li>",
"     <li>",
"      Among secondary outcome measures, plasma exchange was associated with a significantly increased proportion of patients who improved by one or more disability grades at four weeks in five trials. Additionally, plasma exchange treatment compared with control was associated with significant improvement as assessed by the time to recover walking without aid, the percentage of patients requiring mechanical ventilation, the duration of ventilation, full muscle strength recovery after one year, and severe sequelae after one year.",
"     </li>",
"     <li>",
"      Plasma exchange was most effective when started within seven days of symptom onset. However, in the North American study that allowed enrollment up to 30 days after symptom onset, there was still an improvement in outcome in the plasma exchange group compared with controls.",
"     </li>",
"     <li>",
"      Four exchanges were superior to two in patients with moderately severe GBS. However, in subjects with severe disease requiring mechanical ventilation, six exchanges were",
"      <strong>",
"       not",
"      </strong>",
"      superior compared with four.",
"     </li>",
"     <li>",
"      The methodologic quality of the trials was generally good. However, none were patient blinded, as sham apheresis was considered unethical. Furthermore, none of the trials were observer blinded, and only two trials [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/14,15\">",
"       14,15",
"      </a>",
"      ] used centralized review of cases in an attempt to minimize unblinded outcome assessment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) is as effective as plasma exchange for the treatment of GBS. This conclusion was reached by a 2012 systematic review and meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/19\">",
"     19",
"    </a>",
"    ] and by a 2012 American Academy of Neurology guideline on IVIG in the treatment of neuromuscular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example of these reports, a 2012 meta-analysis found no significant difference in the primary outcome measure, the change in a seven-grade disability scale at four weeks, with IVIG compared with plasma exchange (weighted mean difference -0.02, 95% CI -0.25 to 0.20) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, there were no statistically significant differences in other outcome measures.",
"   </p>",
"   <p>",
"    There are no randomized controlled trials comparing IVIG with placebo for the treatment of GBS; rather, the trials have compared IVIG with plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. The 2012 meta-analysis found that patients assigned to IVIG were significantly less likely to discontinue treatment than patients assigned to plasma exchange (relative risk 0.14, 95% CI 0.05-0.36) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with more severe clinical disease may benefit from longer duration of IVIG treatment. This observation is suggested but not established by a small study that compared outcomes in 39 patients with contraindications to plasma exchange randomly assigned to either three or six days of IVIG 0.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/24\">",
"     24",
"    </a>",
"    ]. The primary outcome measure (time until patients were able to stand with assistance) was nonsignificantly shorter in the group treated with IVIG for six days compared with those treated for three days. However, six days of treatment significantly improved the rate of recovery for the subgroup of patients who required mechanical ventilation. A trial studying the efficacy of a repeat course of IVIG in severely affected patients has been planned.",
"   </p>",
"   <p>",
"    A retrospective analysis of randomized trial data found that the increase in serum levels of IgG after IVIG treatment compared with baseline varied considerably among patients with GBS, and that a small increase in serum IgG levels two weeks after treatment was associated with a worse clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/25\">",
"     25",
"    </a>",
"    ]. These data suggest that a higher dose or a repeat course of IVIG may be useful in patients with a small increase in serum IgG, but this hypothesis requires confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combining IVIG with plasma exchange does not appear to be beneficial for patients with GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/20\">",
"     20",
"    </a>",
"    ]. Supporting evidence comes from a trial of 379 nonambulatory patients with severe GBS who were within two weeks of symptom onset and were randomly assigned to treatment with five or six plasma exchanges, or five days of IVIG, or plasma exchange followed by IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/23\">",
"     23",
"    </a>",
"    ]. There were no significant differences in measures of recovery among patients treated with plasma exchange, IVIG, or the combination of plasma exchange and IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the mainstay of therapy for GBS, glucocorticoids have not been shown to be beneficial and no longer have a role [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In a systematic review and meta-analysis of six trials with 587 participants, glucocorticoid-treated patients with GBS showed no significant difference in disability grade, the primary outcome measure, compared with patients who were not treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/29\">",
"     29",
"    </a>",
"    ]. Furthermore, in four small trials, patients treated with oral glucocorticoids had significantly less improvement than patients who were not treated with oral glucocorticoids.",
"   </p>",
"   <p>",
"    One randomized controlled trial found that combined treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and IVIG showed no significant benefit compared with IVIG alone for patients with GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aside from plasma exchange and intravenous immune globulin (IVIG), no other pharmacologic agents have been found to be effective for GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/31\">",
"     31",
"    </a>",
"    ]. Interferon-beta has been reported to be beneficial in individual cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], but in a small randomized controlled trial, interferon-beta therapy was not associated with significant clinical improvement, and possible medication-related side effects were common [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-modifying therapy with plasma exchange or IVIG is recommended for nonambulatory patients with GBS who present within four weeks of neuropathic symptom onset. Therapy with plasma exchange or IVIG is suggested for ambulatory patients with GBS who present within the same time frame, except for those who are mildly affected and already recovering. Patients recover sooner and better when treated early.",
"   </p>",
"   <p>",
"    The choice between plasma exchange and IVIG is dependent on local availability and on patient-related risk factors, contraindications, and preference. Because of its ease of administration and wide availability, IVIG is frequently the preferred treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American Academy of Neurology (AAN) have made the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/20,35\">",
"     20,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment with plasma exchange or IVIG hastens recovery from GBS",
"     </li>",
"     <li>",
"      The beneficial effects of plasma exchange and IVIG are equivalent",
"     </li>",
"     <li>",
"      Combining the two treatments is not beneficial",
"     </li>",
"     <li>",
"      Glucocorticoid treatment alone is not beneficial",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AAN recommends plasma exchange or IVIG for GBS treatment as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma exchange is recommended for nonambulatory adult patients with GBS who start treatment within four weeks of the onset of neuropathic symptoms. Plasma exchange is also recommended for ambulatory patients who start treatment within two weeks of the onset of neuropathic symptoms",
"     </li>",
"     <li>",
"      IVIG is recommended for nonambulatory adult patients with GBS who start treatment within two or possibly four weeks of the onset of neuropathic symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Doses and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin is given for five days at 0.4",
"    <span class=\"nowrap\">",
"     gram/kg",
"    </span>",
"    per day. Side effects include aseptic meningitis, rash, acute renal failure (mostly related to sucrose containing products), and (rarely) hyperviscosity leading to stroke. IgA deficiency can lead to anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma exchange is usually given for four to six treatments over eight to 10 days. The main complications are hypotension, sepsis, and problems with intravenous access. The implementation of therapeutic plasma exchange, including techniques and regimens, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78344571\">",
"    <span class=\"h2\">",
"     Retreatment for poor response or relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with GBS may continue to deteriorate after initial treatment with plasma exchange or intravenous immune globulin (IVIG). This may reflect the natural history of the disease or an error in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/26,36\">",
"     26,36",
"    </a>",
"    ]. Thus, it is useful to confirm that the diagnosis of GBS is correct prior to retreatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data from randomized trials to guide retreatment for patients with poor response or relapse after initial treatment for GBS. We suggest observing the patient for one week after finishing treatment. For those who show no improvement or further deterioration and are severely affected, we suggest retreating with the same modality (plasma exchange or IVIG), under close observation for side effects. We suggest not switching from IVIG to plasma exchange because it will remove the potentially beneficial circulating IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of Guillain-Barr&eacute; syndrome (GBS) is illustrated by a retrospective series of 162 patients who were evaluated in the era before the advent of disease-modifying treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/37\">",
"     37",
"    </a>",
"    ]. Most (74 percent) showed continued progression for up to two weeks, followed by a plateau phase of two to four weeks, and then recovery of function. At four weeks after onset, recovery was underway in 67 percent of patients.",
"   </p>",
"   <p>",
"    The time period to onset of recovery is shortened by about 40 to 50 percent by treatment with plasma exchange or IVIG. Data from the North American plasma exchange trial that studied 245 patients treated within 30 days after onset of motor deficit illustrates the degree of improvement with disease-modifying therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median time to improve one grade in the plasma exchange and control groups was 19 and 40 days",
"     </li>",
"     <li>",
"      The median time to walking unaided in the plasma exchange and control groups was 53 and 85 days",
"     </li>",
"     <li>",
"      Improvement by at least one grade at one month in the plasma exchange and control groups occurred in 59 and 39 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with a poor prognosis for recovery from GBS include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Rapid onset (less than seven days) prior to presentation",
"     </li>",
"     <li>",
"      Severe muscle weakness on admission",
"     </li>",
"     <li>",
"      Need for ventilatory support",
"     </li>",
"     <li>",
"      An average distal motor response amplitude reduction to &lt;20 percent of normal",
"     </li>",
"     <li>",
"      Preceding diarrheal illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study that analyzed 388 patients with GBS from two randomized controlled trials and a pilot study, independent predictors of poor six-month outcome (defined as the inability to walk 10 m without assistance) were age, preceding diarrhea, and the degree of disability at two weeks after study entry [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although initial studies suggested a possible correlation between anti-GM1 antibodies and poor recovery, a prospective trial of 96 patients with GBS from Great Britain found no such correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiology studies can have prognostic value, especially when repeated over the first five weeks. Axonal degeneration and poor prognosis (ie, slower recovery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe residual disability) are suggested by markedly reduced distal motor response amplitude (&lt;20 percent of normal) and profuse fibrillation potentials on needle examination, starting at two to four weeks after disease onset. In contrast, demyelination and a good prognosis are associated with a pattern characterized by preservation of the distal motor response amplitude above 20 percent of normal, conduction block, and temporal dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of patients with GBS who walk independently at six months and one year after diagnosis is approximately 80 and 84 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/41\">",
"     41",
"    </a>",
"    ]. At one year, full recovery of motor strength occurs in about 60 percent of patients, while severe motor problems persist in about 14 percent. Approximately 5 to 10 percent of patients with GBS have a prolonged course with several months of ventilator dependency and very delayed and incomplete recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within one year of diagnosis, approximately 5 percent of patients with GBS die despite intensive care [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/41,46\">",
"     41,46",
"    </a>",
"    ]. Of patients who become ventilator dependent, about 20 percent will die. Causes of death include acute respiratory distress syndrome, sepsis, pulmonary emboli, and unexplained cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Relapses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses with increased weakness occur in up to 10 percent of patients with GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Relapses are usually treated with a partial or complete repeat course of the initial plasma exchange or IVIG treatment. (See",
"    <a class=\"local\" href=\"#H78344571\">",
"     'Retreatment for poor response or relapse'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    About 2 percent of GBS patients will develop the chronic relapsing weakness of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;While Guillain-Barr&eacute; syndrome (GBS) has followed vaccinations, the true risk of vaccine-associated GBS is uncertain. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, vaccination in patients with GBS should be considered on an individual basis. The following recommendations are in agreement with a 2005 expert review of supportive care for patients with GBS, and are based on observational studies and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunizations are not recommended during the acute phase of GBS and are not suggested for a period of one year or more after the onset of GBS",
"     </li>",
"     <li>",
"      After one year, immunizations need not be withheld, but the need for the immunization should be reviewed on an individual basis",
"     </li>",
"     <li>",
"      Future avoidance is suggested for any particular immunization that is followed within six weeks by the onset of GBS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the majority of patients who have risk factors for severe influenza complications and who have a history of GBS not provoked by influenza vaccination, the established benefits of influenza vaccination justifies yearly vaccination. The utility of influenza vaccination in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/37/37457?source=see_link\">",
"       \"Patient information: Guillain-Barr&eacute; syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care is extremely important in Guillain-Barr&eacute; syndrome (GBS) since about 30 percent of patients develop neuromuscular respiratory failure requiring mechanical ventilation. In addition, severe autonomic dysfunction occurs in about 20 percent and warrants intensive care unit (ICU) monitoring. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Close respiratory monitoring with frequent measurement of vital capacity and negative inspiratory force should be instituted in all patients with GBS on admission and continued while weakness is progressing. Patients with a forced vital capacity &lt;20",
"      <span class=\"nowrap\">",
"       mL/kg,",
"      </span>",
"      maximum inspiratory pressure &lt;30 cmH2O, or maximum expiratory pressure &lt;40 cmH2O are at high risk of impending respiratory failure and should undergo urgent intubation and mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Respiratory failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with GBS and progressive weakness, we recommend cardiac and blood pressure monitoring. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cardiovascular management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with GBS and progressive weakness, we recommend daily abdominal auscultation to monitor for bowel silence and the development of adynamic ileus. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bowel and bladder care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropathic pain occurs in about 40 to 50 percent of patients during the course of GBS and often requires treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of disease-modifying treatment, most patients with GBS show continued progression for up to two weeks, followed by a plateau phase of about two weeks, and then recovery of function over several weeks to months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Disease modifying treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main modalities of disease modifying therapy for GBS are plasma exchange and intravenous immune globulin (IVIG). The treatments are equivalent and improve outcome. Treatment shortens the time to walking independently by 40 to 50 percent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Disease modifying treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For nonambulatory adult patients with GBS who are within four weeks of neuropathic symptom onset, we recommend treatment with plasma exchange or IVIG (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For ambulatory adult patients with GBS who are not yet recovering within four weeks of neuropathic symptom onset, we suggest treatment with plasma exchange or IVIG (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The choice between plasma exchange and IVIG is dependent on local availability and on patient preference, risk factors, and contraindications. When both therapies are equally available and there are no contraindications for either, we suggest treatment with IVIG (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Plasma exchange'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adult patients with GBS, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      treating with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even with treatment, approximately 5 to 10 percent of patients have a prolonged course with very delayed and incomplete recovery, and 5 percent die despite intensive care. In addition, relapses occur in up to 10 percent of patients. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/1\">",
"      Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barr&eacute; syndrome. Arch Neurol 2005; 62:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/2\">",
"      Zochodne DW. Autonomic involvement in Guillain-Barr&eacute; syndrome: a review. Muscle Nerve 1994; 17:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/3\">",
"      Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barr&eacute; syndrome. Arch Neurol 2001; 58:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/4\">",
"      Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barr&eacute; syndrome. Crit Care Med 2003; 31:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/5\">",
"      Hund EF, Borel CO, Cornblath DR, et al. Intensive management and treatment of severe Guillain-Barr&eacute; syndrome. Crit Care Med 1993; 21:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/6\">",
"      Truax, BT. Autonomic disturbances in Guillain-Barre syndrome. Semin Neurol 1984; 4:462.",
"     </a>",
"    </li>",
"    <li>",
"     Ropper, AH. Critical care of Guillain-Barre syndrome. In: Neurological and neurosurgical intensive care, 4th ed, Ropper, AH (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/8\">",
"      Moulin DE, Hagen N, Feasby TE, et al. Pain in Guillain-Barr&eacute; syndrome. Neurology 1997; 48:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/9\">",
"      Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in guillain-barr&eacute; syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002; 95:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/10\">",
"      Meythaler JM. Rehabilitation of Guillain-Barr&eacute; syndrome. Arch Phys Med Rehabil 1997; 78:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/11\">",
"      Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr&eacute; syndrome. Ann Neurol 2002; 51:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/12\">",
"      Jacobs BC, O'Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/13\">",
"      Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/14\">",
"      Plasmapheresis and acute Guillain-Barr&eacute; syndrome. The Guillain-Barr&eacute; syndrome Study Group. Neurology 1985; 35:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/15\">",
"      Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/16\">",
"      Efficiency of plasma exchange in Guillain-Barr&eacute; syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barr&eacute; syndrome. Ann Neurol 1987; 22:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/17\">",
"      Appropriate number of plasma exchanges in Guillain-Barr&eacute; syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barr&eacute; Syndrome. Ann Neurol 1997; 41:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/18\">",
"      Rapha&euml;l JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barr&eacute; syndrome. Cochrane Database Syst Rev 2012; 7:CD001798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/19\">",
"      Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr&eacute; syndrome. Cochrane Database Syst Rev 2012; 7:CD002063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/20\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/21\">",
"      van der Mech&eacute; FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr&eacute; syndrome. Dutch Guillain-Barr&eacute; Study Group. N Engl J Med 1992; 326:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/22\">",
"      Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr&eacute; syndrome. Neurology 1996; 46:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/23\">",
"      Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr&eacute; syndrome. Plasma Exchange/Sandoglobulin Guillain-Barr&eacute; Syndrome Trial Group. Lancet 1997; 349:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/24\">",
"      Raphael JC, Chevret S, Harboun M, et al. Intravenous immune globulins in patients with Guillain-Barr&eacute; syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001; 71:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/25\">",
"      Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr&eacute; syndrome. Ann Neurol 2009; 66:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/26\">",
"      Cornblath DR, Hughes RA. Treatment for Guillain-Barr&eacute; syndrome. Ann Neurol 2009; 66:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/27\">",
"      Hughes RA. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barr&eacute; syndrome. Lancet 1991; 338:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/28\">",
"      Double-blind trial of intravenous methylprednisolone in Guillain-Barr&eacute; syndrome. Guillain-Barr&eacute; Syndrome Steroid Trial Group. Lancet 1993; 341:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/29\">",
"      Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barr&eacute; syndrome. Cochrane Database Syst Rev 2012; 8:CD001446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/30\">",
"      van Koningsveld R, Schmitz PI, Mech&eacute; FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr&eacute; syndrome: randomised trial. Lancet 2004; 363:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/31\">",
"      Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr&eacute; syndrome. Cochrane Database Syst Rev 2013; 2:CD008630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/32\">",
"      Cr&eacute;ange A, Lerat H, Meyrignac C, et al. Treatment of Guillain-Barr&eacute; syndrome with interferon-beta. Lancet 1998; 352:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/33\">",
"      Schaller B, Radziwill AJ, Steck AJ. Successful treatment of Guillain-Barr&eacute; syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. Eur Neurol 2001; 46:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/34\">",
"      Pritchard J, Gray IA, Idrissova ZR, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr&eacute; syndrome. Neurology 2003; 61:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/35\">",
"      Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barr&eacute; syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/36\">",
"      Winer JB. When the Guillain-Barre patient fails to respond to treatment. Pract Neurol 2009; 9:227.",
"     </a>",
"    </li>",
"    <li>",
"     Ropper, AH, Wijdicks, EFM, Truax, BT. Guillain-Barr&eacute; syndrome, FA Davis, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/38\">",
"      McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barr&eacute; syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988; 23:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/39\">",
"      Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barr&eacute; syndrome. N Engl J Med 1995; 333:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/40\">",
"      Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 2011; 76:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/41\">",
"      Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2012; 83:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/42\">",
"      van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barr&eacute; syndrome. Lancet Neurol 2007; 6:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/43\">",
"      Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barr&eacute; syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/44\">",
"      Albers JW. AAEE case report #4: Guillain-Barr&eacute; syndrome. Muscle Nerve 1989; 12:705.",
"     </a>",
"    </li>",
"    <li>",
"     Kissel, JT, Cornblath, DR, Mendell, JR. Guillain-Barre syndrome. In: Diagnosis and management of peripheral nerve disorders, Oxford University Press, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/46\">",
"      Chi&ograve; A, Cocito D, Leone M, et al. Guillain-Barr&eacute; syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003; 60:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/47\">",
"      Lawn ND, Wijdicks EF. Fatal Guillain-Barr&eacute; syndrome. Neurology 1999; 52:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/48\">",
"      WIEDERHOLT WC, MULDER DW, LAMBERT EH. THE LANDRY-GUILLAIN-BARR'E-STROHL SYNDROME OR POLYRADICULONEUROPATHY: HISTORICAL REVIEW, REPORT ON 97 PATIENTS, AND PRESENT CONCEPTS. Mayo Clin Proc 1964; 39:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/49\">",
"      Asbury AK. New concepts of Guillain-Barr&eacute; syndrome. J Child Neurol 2000; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/265/abstract/50\">",
"      Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barr&eacute; syndrome. J Neurol 2003; 250:913.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5172 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_265=[""].join("\n");
var outline_f0_16_265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiovascular management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bowel and bladder care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISEASE MODIFYING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Doses and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78344571\">",
"      Retreatment for poor response or relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Relapses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/37/37457?source=related_link\">",
"      Patient information: Guillain-Barr&eacute; syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=related_link\">",
"      Treatment of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_266="Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation";
var content_f0_16_266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     Walter L. Biffl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     Clay Cothren Burlew, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     Ernest E Moore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/266/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/16/266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/16/266/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/16/266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19563948\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt carotid and vertebral artery injury, collectively termed blunt cerebrovascular injury, are rare but potentially devastating events. Blunt carotid injury is associated with mortality rates that range from 23 to 28 percent with 48 to 58 percent of survivors suffering permanent severe neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence is low in patients sustaining blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Clinical studies in the early 1990s suggested that these injuries were being under-diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Increased recognition through screening (arteriography, computed tomographic angiography) based upon specific clinical criteria has increased the reported incidence to about one percent in patients with blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/1,7-9\">",
"     1,7-9",
"    </a>",
"    ]. When such injury occurs, it is often bilateral.",
"   </p>",
"   <p>",
"    Injury mechanisms, screening, and diagnosis of blunt cerebrovascular injury will be reviewed here. The treatment of blunt cerebrovascular injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and management of penetrating cerebrovascular injury and spontaneous cerebrovascular dissection are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=see_link\">",
"     \"Penetrating neck injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link\">",
"     \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19563955\">",
"    <span class=\"h1\">",
"     CEREBROVASCULAR ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular supply to the brain is divided into the anterior and posterior circulations originating from the carotid and vertebral arteries, respectively. The circle of Willis connects the anterior and posterior circulations, but is completely intact and symmetric in only about 20 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/10\">",
"     10",
"    </a>",
"    ]. The anatomic variability of the collateral circulation helps explain the clinical presentations of patients with cerebrovascular injuries, and underscores the need for complete imaging of cerebral circulation when injury is suspected. (See",
"    <a class=\"local\" href=\"#H3987108\">",
"     'Imaging evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979546\">",
"    <span class=\"h2\">",
"     Anterior circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior circulation supplies the majority of the cerebral hemispheres except the occipital and medial temporal lobes. Injury to the vessels of the anterior circulation can lead to ischemic or hemorrhagic hemispheric stroke. (See",
"    <a class=\"local\" href=\"#H3979590\">",
"     'Clinical presentation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The left common carotid artery (CCA) originates from the aortic arch, whereas the right CCA originates from the brachiocephalic trunk (innominate artery) (",
"    <a class=\"graphic graphic_figure graphicRef51410 \" href=\"UTD.htm?2/4/2122\">",
"     figure 1",
"    </a>",
"    ). The CCA divides into the internal carotid artery (ICA) and external carotid artery (ECA) at the level of the superior border of the thyroid cartilage corresponding to the disc space between the third and fourth cervical vertebral bodies",
"    <span class=\"nowrap\">",
"     (C3/C4).",
"    </span>",
"   </p>",
"   <p>",
"    The external carotid artery (ECA) has multiple branches which supply the face and scalp (",
"    <a class=\"graphic graphic_figure graphicRef50495 \" href=\"UTD.htm?31/61/32728\">",
"     figure 2",
"    </a>",
"    ) and provide collateral circulation to the brain. Traumatic injuries to the ECA are usually tolerated neurologically with the occasional exception of patients with pre-existing cerebrovascular disease. When the ICAs or vertebral arteries (VA) have significant stenoses or occlusion, the ECA branches may provide critical collateral pathways for cerebral blood flow (",
"    <a class=\"graphic graphic_figure graphicRef82579 \" href=\"UTD.htm?31/46/32487\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2918748\">",
"    <span class=\"h3\">",
"     Internal carotid artery segments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICA (",
"    <a class=\"graphic graphic_figure graphicRef63286 \" href=\"UTD.htm?4/48/4874\">",
"     figure 4",
"    </a>",
"    ) is divided into four segments based upon anatomic landmarks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical &ndash; The cervical portion usually has no named branches as it ascends anterior to the spine. Blunt trauma to the neck in this region can lead to compression of the ICA against the transverse processes of the first through third (C1-C3) vertebral bodies.",
"     </li>",
"     <li>",
"      Petrous &ndash; The petrous segment traverses the carotid canal in the petrous portion of the temporal bone. Basilar skull fractures can cause laceration of the ICA at this site.",
"     </li>",
"     <li>",
"      Cavernous &ndash; The cavernous portion, also called the carotid siphon because of its S-shape, is the first portion of the ICA within the cranial vault. This segment is suspended between the layers of the dura mater that form the cavernous sinus. Fracture of the sphenoid bone may injure the cavernous portion.",
"     </li>",
"     <li>",
"      Cerebral",
"      <strong>",
"      </strong>",
"      &ndash; The ICA perforates the dura mater at the anterior clinoid process to become the cerebral (or supraclinoid) segment which divides into the anterior and middle cerebral arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979568\">",
"    <span class=\"h2\">",
"     Posterior circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior circulation supplies the midbrain, cerebellum, occipital lobe and medial temporal lobes. Injuries to the vessels that supply these regions can lead to a variety of syndromes depending upon the specific nature of the injury (See",
"    <a class=\"local\" href=\"#H3979590\">",
"     'Clinical presentation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"     \"Posterior circulation cerebrovascular syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The VAs most commonly originate from the subclavian arteries, although some variation can occur. The VAs originate directly from the aortic arch in 3 to 5 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/12\">",
"     12",
"    </a>",
"    ]. The VAs are commonly asymmetric in diameter and it is not uncommon for one VA to be atretic, a finding that is slightly more common on the left than the right [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VA traverses the neck anterior to the scalene muscle, enters the vertebral foramina of the sixth cervical vertebra and exits the transverse foramina of the second cervical vertebra.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2918703\">",
"    <span class=\"h3\">",
"     Vertebral segments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VA is divided into four anatomic segments (V1-V4) (",
"    <a class=\"graphic graphic_figure graphicRef56466 \" href=\"UTD.htm?36/0/36867\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      V1 &ndash; Origin of the vessel to the foramina of the sixth cervical (C6) transverse process.",
"     </li>",
"     <li>",
"      V2 &ndash; Intraforaminal segment from the sixth to the second cervical vertebral body (C6 to C2).",
"     </li>",
"     <li>",
"      V3 &ndash; From the second cervical (C2) foramina to the base of the skull",
"     </li>",
"     <li>",
"      V4 &ndash; Intracerebral segment of the vertebral artery. The vertebral arteries merge to form the basilar artery and are intradural.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182474602\">",
"    <span class=\"h2\">",
"     Site of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral cerebrovascular injuries are common, occurring in 18 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/4,6,13\">",
"     4,6,13",
"    </a>",
"    ]. Carotid injuries appear to occur more frequently than vertebral injuries. In a retrospective review of 171 patients found to have blunt cerebrovascular injury, 114 patients had 157 carotid artery injuries and 79 patients had 97 vertebral artery injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/6\">",
"     6",
"    </a>",
"    ]. However, some studies have shown equal number or a preponderance of vertebral injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219286045\">",
"    <span class=\"h1\">",
"     MECHANISMS OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of trauma mechanisms including motor vehicle crashes, falls, assaults, and suicide attempts can result in blunt cerebrovascular injury. Motor vehicle crashes account for more than half of blunt cerebrovascular injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/4,6,13\">",
"     4,6,13",
"    </a>",
"    ]. The absence of trauma from an individual&rsquo;s history does not exclude trauma as an etiology, because patients often consider the inciting event to be insignificant or too embarrassing to tell their physician.",
"   </p>",
"   <p>",
"    Blunt injury to the carotid or vertebral arteries is usually the result of a significant force that twists or stretches the vessel, or impinges the vessel against the underlying bone, often for only a brief period of time. The carotid or vertebral artery may also be lacerated by bone that has fractured.",
"   </p>",
"   <p>",
"    In 1974 four fundamental mechanisms of blunt carotid injuries were described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I carotid injuries involve the direct application of force to the neck (eg, seatbelt, strangulation, near-hanging) and account for up to about 10 percent of blunt carotid injuries.",
"     </li>",
"     <li>",
"      Type II carotid injuries are due to hyperextension and contralateral rotation of the head and neck (",
"      <a class=\"graphic graphic_figure graphicRef56047 \" href=\"UTD.htm?26/17/26899\">",
"       figure 6",
"      </a>",
"      ). This is probably the most common mechanism of injury. The lateral articular processes and pedicles of the upper three cervical vertebrae (C1-C3) project more anteriorly than those of the lower four cervical (C4-C7) vertebrae. Thus, in the upper region, the cervical internal carotid artery (ICA) can be stretched across the lateral processes with cervical hyperextension. Rotation at the atlanto-axial joint aggravates stretch injury because it can cause anterior movement of the contralateral C1 transverse process [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type III carotid injuries involve intraoral trauma that affect the internal carotid artery at the angle of the jaw (",
"      <a class=\"graphic graphic_figure graphicRef56047 \" href=\"UTD.htm?26/17/26899\">",
"       figure 6",
"      </a>",
"      ). This type of injury is seen in patients who fall with a hard object in the mouth such as in children who have fallen with a toothbrush in their mouth [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type IV injuries are due to laceration of the carotid artery resulting from basilar skull fracture, most commonly in the region of the carotid canal [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/19\">",
"       19",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the underlying mechanism of injury, the pathologic insult in most cases is an intimal tear. The exposed subendothelial collagen promotes platelet aggregation and thrombus formation, which may occlude the vessel altogether or embolize to the cerebral circulation.",
"   </p>",
"   <p>",
"    The intimal tear may remain static or there may be a subintimal dissection that progresses cranially, which can cause luminal narrowing or acute vessel occlusion as the false lumen collapses against the true lumen. Less commonly, partial or complete transection of the artery occurs, resulting in pseudoaneurysm formation or free rupture. A pseudoaneurysm may increase in size to compress and occlude the vessel lumen, or rupture; if it contains thrombus, it may be a source of platelet thromboembolism. Rupture may result in intracranial or extracranial hemorrhage, or formation of an arteriovenous fistula.",
"   </p>",
"   <p>",
"    Other cerebrovascular injury mechanisms have been reported. As an example, numerous case reports document blunt injuries (mostly dissection) following mechanisms that would not typically raise a suspicion for injury, so-called &ldquo;trivial trauma.&rdquo; These mechanisms include chiropractic manipulation, hyperflexion or hyperextension during hair washing, &ldquo;head banging&rdquo; to music, &ldquo;bottoms-up&rdquo; drinking, rapid head turning, virtually any athletic endeavor, and everyday activities such as coughing, shaving, vomiting, and nose-blowing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &ldquo;Spontaneous&rdquo; carotid and vertebral artery dissections occur in the absence of apparent etiologic factors and account for about 2 to 3 percent of primary strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/20\">",
"     20",
"    </a>",
"    ]. Risk factors include hypertension, Marfan syndrome, fibromuscular dysplasia, syphilis, arteriopathies, and Erdheim&rsquo;s cystic medial necrosis. Some speculate that the presence of these medical risk factors (whether or not their presence is known) predisposes these patients to cerebrovascular injury following lesser degrees of trauma. Spontaneous carotid and vertebral artery dissections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link\">",
"     \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3981270\">",
"    <span class=\"h1\">",
"     TRAUMA EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial resuscitation, diagnostic evaluation, and management of the patient with blunt or penetrating injury is based upon protocols from the Advanced Trauma Life Support (ATLS&reg;) program, established by the American College of Surgeons Committee on Trauma. The initial resuscitation and evaluation of the patient with blunt trauma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H25#H25\">",
"     \"Facial trauma in adults\", section on 'Midface'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219286132\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt cerebrovascular injury is associated with mechanisms that can cause severe head, facial, spine, chest, and abdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/2,7-9\">",
"     2,7-9",
"    </a>",
"    ]. In a review of 171 patients with blunt cerebrovascular injury, the average injury severity score was 28 &plusmn; 1, which is consistent with other reports. Associated injuries included the brain (57 percent), spine (44 percent), chest (43 percent), and face (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical spine fracture has the strongest association with blunt cerebrovascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A systematic review and metaanalysis identified only cervical spine injury and thoracic injury as significantly increasing the risk for blunt cerebrovascular injury (odds ratio [OR] 5.45, 95% CI 2.24-13.27, OR 1.98, 95% CI 1.35-2.92, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/22\">",
"     22",
"    </a>",
"    ]. In a retrospective review that stratified cervical spine fractures as high-risk (C1-C3) or low-risk (isolated, low [C4-C7]) for blunt cerebrovascular injury, the incidence of blunt cerebrovascular injury was 8 and 2 percent, respectively, suggesting the need to screen all cervical spine injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19564013\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Delayed recognition of blunt cerebrovascular injury may result from the need for clinicians to manage life-threatening thoracic or abdominal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/9\">",
"     9",
"    </a>",
"    ]. In some cases, a meaningful neurologic examination is not possible due to head injuries or the need to sedate or intubate the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979590\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of blunt cerebrovascular injury can vary greatly depending upon the vessel affected, site of injury, injury grade and any pre-existing cerebrovascular disease. (See",
"    <a class=\"local\" href=\"#H19563955\">",
"     'Cerebrovascular anatomy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H280052#H280052\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Injury grading'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 80 percent of patients with blunt cerebrovascular injury have no obvious neurologic manifestations at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/6\">",
"     6",
"    </a>",
"    ]. A latent period between the time of injury and the appearance of clinical manifestations is typically seen. Unless the vessel immediately occludes, time is required for thrombus formation that might limit flow or lead to distal embolization. In various studies, 25 to 50 percent of patients first developed signs or symptoms of blunt carotid injury more than 12 hours after the traumatic event [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/4,9,24-28\">",
"     4,9,24-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations have been made in studies in which screening for cerebrovascular injury was performed in patients with blunt trauma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 17 patients diagnosed with blunt cerebrovascular injury identified from 3480 blunt trauma admissions, 10 deaths were attributable to the injury [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/9\">",
"       9",
"      </a>",
"      ]. The median time until diagnosis was 12.5 hours for the entire group and 19.5 hours for non-survivors. Four of five patients whose diagnosis was delayed for more than 48 hours did not survive.",
"     </li>",
"     <li>",
"      In an analysis of 45 blunt cerebrovascular injury-related strokes occurring in patients who could not receive antithrombotic therapy, 11 out of 45 occurred within two hours of injury; the average time to stroke in the remaining 34 of 45 patients was 75 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another retrospective review of 76 patients with blunt cerebrovascular injury, 42 percent of symptomatic patients manifested symptoms more than 18 hours following injury, with two patients becoming symptomatic at seven days [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The average time to stroke can range from two hours to one week, but most occurs between 12 and 75 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/4,9,24-30\">",
"       4,9,24-30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When neurologic manifestations of cerebral ischemia occur, the symptoms and findings on neurologic examination depend upon the specific artery involved, the presence (or absence) of adequate collateral circulation (",
"    <a class=\"graphic graphic_figure graphicRef82579 \" href=\"UTD.htm?31/46/32487\">",
"     figure 3",
"    </a>",
"    ), and the presence (or absence) of underlying cerebrovascular disease. Approximately 10 to 15 percent of symptomatic patients have lateralizing symptoms, and at least 50 percent develop a completed stroke. No single neurologic finding allows a precise diagnosis, but the constellation of findings may identify the involved artery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/2\">",
"     2",
"    </a>",
"    ]. The manifestations of cerebral ischemia are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=see_link\">",
"     \"Etiology and clinical manifestations of transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"     \"Etiology and classification of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"     \"Posterior circulation cerebrovascular syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain clinical signs are so suggestive of blunt cerebrovascular injury that they should prompt emergent diagnostic evaluation, usually with CT (see",
"    <a class=\"local\" href=\"#H3987108\">",
"     'Imaging evaluation'",
"    </a>",
"    below). These include acute arterial hemorrhage from the neck, mouth, nose, or ear; expanding cervical hematoma; cervical bruit in a patient younger than 50 years of age; and focal or lateralizing neurologic deficits (eg, hemiparesis, transient ischemic attack, Horner's syndrome, oculosympathetic paresis, vertebrobasilar insufficiency) (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ). Patients with acute hemorrhage are treated to limit the amount of blood loss and prevent shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H280052#H280052\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Injury grading'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms such as, neck, ear, face, or periorbital pain occur in up to 60 percent of patients with carotid or vertebral artery dissection in the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/31\">",
"     31",
"    </a>",
"    ]. However, pain may be difficult to elicit in the multiply-injured patient, or may be attributed to other injuries. Thus, any patient with neck pain or headache following blunt trauma should be suspected of having cerebrovascular injury.",
"   </p>",
"   <p>",
"    Neurologic signs associated with local arterial injury, which occur in approximately 5 percent of symptomatic patients, suggest that blunt cerebrovascular injury has occurred even though patients have no manifestations of cerebral ischemia. As an example, blunt carotid injury can disrupt the periarterial sympathetic plexus, leading to Horner&rsquo;s syndrome (ptosis, myosis, anhidrosis) or oculosympathetic paresis, which is a partial Horner&rsquo;s syndrome that includes ptosis and miosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"     \"Horner's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although pupillary asymmetry can have a number of etiologies in the trauma patient, blunt cerebrovascular injury should be suspected ipsilateral to the side of the smaller pupil if the larger of the pupils is reactive and the smaller pupil is not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564013\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for blunt cerebrovascular injury has been controversial. As described in the preceding section, a majority of patients with blunt cerebrovascular injury do not have neurologic symptoms at presentation but may develop signs or symptoms hours or days later. (See",
"    <a class=\"local\" href=\"#H3979590\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most clinicians feel that this delay provides a window of opportunity during which patients at risk for adverse outcomes can be identified and stroke-prevention therapy initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/1,7,33,34\">",
"     1,7,33,34",
"    </a>",
"    ]. Screening has clearly increased the number of blunt cerebrovascular injuries being diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/6,14,33,35-37\">",
"     6,14,33,35-37",
"    </a>",
"    ]. Although failure to identify and treat blunt cerebrovascular injury when symptoms occur results in significant morbidity and mortality, it is unclear whether aggressive screening leads to improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H259262#H259262\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Stroke and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators have suggested that blunt cerebrovascular injury cannot be reliably predicted based upon the injury mechanism and clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/40\">",
"     40",
"    </a>",
"    ]. However, others have critically evaluated specific injury mechanisms, patterns of injury, and clinical symptoms and signs of blunt cerebrovascular injury to define criteria by which to perform diagnostic testing. (See",
"    <a class=\"local\" href=\"#H4011653\">",
"     'Indications for imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the earliest study of screening, 171 patients with indications to exclude thoracic aortic injury using arteriography also underwent carotid arteriography. Although these patients had no symptoms or signs to suggest blunt cerebrovascular injury, 3.5 percent of the studies were positive [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/41\">",
"     41",
"    </a>",
"    ]. Subsequently, using defined clinical criteria, blunt cerebrovascular injury was identified in 27 percent of the asymptomatic patients screened [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/42\">",
"     42",
"    </a>",
"    ]. After instituting a policy of screening, the incidence of blunt carotid injury increased from 0.1 to 1.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. These findings have been replicated at several other trauma centers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/14,33,35-38\">",
"     14,33,35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multivariate analysis identified independent risk factors for blunt carotid injury (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ) that included Glasgow coma scale (GCS) &lt;6 (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ), petrous bone fracture, diffuse axonal brain injury, and LeFort II or LeFort III fracture (",
"    <a class=\"graphic graphic_figure graphicRef55687 \" href=\"UTD.htm?2/57/2966\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/42\">",
"     42",
"    </a>",
"    ]. The presence of any one of these factors identified 41 percent of the patients with blunt carotid injury and increased to 93 percent in the presence of all four factors. On the other hand, 20 percent of patients who had blunt cerebrovascular injury did not have any of these risk factors. The only independent predictor of blunt vertebral artery injury was cervical spine fracture.",
"   </p>",
"   <p>",
"    Another retrospective review used the above criteria to screen patients for blunt cerebrovascular injury and included additional criteria to capture specific cervical spine fracture patterns (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/34\">",
"     34",
"    </a>",
"    ]. Of those who met the screening criteria, 244 patients had a blunt cerebrovascular injury for an incidence of 1.5 percent. Carotid and vertebral injuries were seen nearly equally (141 carotid, 124 vertebral). More than one injury was seen in 37 percent of the patients.",
"   </p>",
"   <p>",
"    Optimal screening criteria continue to be debated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/33,43-45\">",
"     33,43-45",
"    </a>",
"    ]. More restrictive criteria might yield a higher proportion of positive results, decreased complications related to arteriography, and lower cost, but an increase in the likelihood of missing an injury in an unscreened patient. The use of noninvasive studies for screening, particularly computed tomography, may allow the criteria used for screening to be broadened [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3987108\">",
"     'Imaging evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282468\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective review that used defined criteria to perform screening arteriography in 727 of 15,767 patients with blunt trauma (4.6 percent), blunt cerebrovascular injury was identified in 244 (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/34\">",
"     34",
"    </a>",
"    ]. Antithrombotic therapy was initiated in 187 asymptomatic patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (117), low molecular-weight heparin (11), or antiplatelet agents (59). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the treated patients suffered a stroke (0.5 percent). In contrast, symptomatic patients who were not able to be anticoagulated had an ischemic neurologic event rate of 21 percent.",
"     </li>",
"     <li>",
"      Using estimated stroke rates for each grade of injury, the authors estimated that 32 neurologic events were averted by the early identification and treatment of asymptomatic patients with blunt cerebrovascular injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H280052#H280052\">",
"       \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Injury grading'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The expense for arteriography was $6800 per patient for a total cost of $4,943,600 in the 727 patients. For each of the 32 estimated neurologic events, an incremental increase in the cost of treatment and rehabilitation over the patient&rsquo;s lifetime that exceeds $154,000 would justify the screening process. The use of less expensive screening modalities, such as computed tomography, might further increase cost savings, but screening a greater proportion of patients would offset this savings. (See",
"      <a class=\"local\" href=\"#H19564013\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4011653\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurovascular imaging is indicated for patients with any clinical symptom or sign suggestive of blunt cerebrovascular injury, patients with unexplained neurologic symptoms and in asymptomatic patients with any of the risk factors listed below (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The following clinical signs are suggestive of blunt cerebrovascular injury in the trauma patient and should prompt emergent evaluation and interventions directed at hemorrhage control or stroke management. (See",
"    <a class=\"local\" href=\"#H3979590\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial hemorrhage from the neck, mouth, nose, or ear",
"     </li>",
"     <li>",
"      Cervical hematoma",
"     </li>",
"     <li>",
"      Cervical bruit in a patient younger than 50 years of age",
"     </li>",
"     <li>",
"      Focal or lateralizing neurologic deficit (eg, hemiparesis, transient ischemic attack, Horner's syndrome, oculosympathetic paresis, vertebrobasilar insufficiency)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following risk factors for blunt cerebrovascular injury have been endorsed by both the Eastern and Western Trauma Associations of the United States to screen",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    patients (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injury mechanism compatible with severe cervical",
"      <span class=\"nowrap\">",
"       hyperextension/rotation",
"      </span>",
"      or hyperflexion",
"     </li>",
"     <li>",
"      LeFort II or LeFort III midface fractures",
"     </li>",
"     <li>",
"      Basilar skull fracture involving the carotid canal",
"     </li>",
"     <li>",
"      Closed head injury consistent with diffuse axonal injury with Glasgow Coma Score &lt;6",
"     </li>",
"     <li>",
"      Cervical vertebral body or transverse foramen fracture, subluxation, or ligamentous injury at any level, or any fracture at the level of C1-C3",
"     </li>",
"     <li>",
"      Near-hanging resulting in cerebral anoxia",
"     </li>",
"     <li>",
"      Clothesline-type injury or seat belt abrasion associated with significant cervical pain, swelling or altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3987108\">",
"    <span class=\"h1\">",
"     IMAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptoms, signs or risk-factors for injury are presumed to have blunt cerebrovascular injury until proven otherwise. (See",
"    <a class=\"local\" href=\"#H4011653\">",
"     'Indications for imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282240\">",
"    <span class=\"h2\">",
"     Imaging modalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564062\">",
"    <span class=\"h3\">",
"     CT angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most studies have used arteriography to screen for blunt cerebrovascular injury, computed tomographic (CT) angiography is becoming the screening test of choice under both urgent and emergent circumstances (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ). This is primarily because patients who are candidates for screening often have indications for scanning other regions of the body such as the head, face, cervical spine, chest and abdomen. Another benefit of CT is a reduction in the volume of contrast needed to perform these studies which can be up to half that needed for arch aortography and four-vessel cerebral arteriography. (See",
"    <a class=\"local\" href=\"#H3981270\">",
"     'Trauma evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4011653\">",
"     'Indications for imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of CT angiography for blunt cerebrovascular injury has increased with improvements in CT technology [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/49\">",
"     49",
"    </a>",
"    ]. Studies comparing one, two or four-slice CT scanners with digital subtraction arteriography have found unacceptably low sensitivities for blunt cerebrovascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/35,50\">",
"     35,50",
"    </a>",
"    ]. The sensitivity of four and eight-slice scanners for blunt carotid injury ranges from 83 to 92 percent and specificity is from 88 to 92 percent, while the sensitivity for blunt vertebral injury ranges from 50 percent to 60 percent with specificity from 90 to 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sixteen slice or greater slice CT angiography is more reliable in the diagnosis of blunt cerebrovascular injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/14,15,36,37,46,51,52\">",
"     14,15,36,37,46,51,52",
"    </a>",
"    ]. Using a 16-slice scanner, the detected incidence of blunt cerebrovascular injury is consistent with that seen using digital subtraction arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Whole-body multidetector-row CT has now been adopted in some centers. It offers more rapid imaging, with a single dose of intravenous contrast. A preliminary report suggests an accuracy equivalent to 16-slice CTA but further evaluation is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true sensitivity of CT angiography can be obtained only by direct comparison to digital subtraction arteriography as the standard. Four studies have performed these comparisons using 16 or 64-slice CT scanners with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/14,15,51,52\">",
"     14,15,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study screened 146 patients for blunt cerebrovascular injury with both arteriography and CT angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/14\">",
"       14",
"      </a>",
"      ]. Injuries were identified in 46 patients (20 carotid, 26 vertebral). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of CT angiography were 98, 100, 100, 99, and 99 percent, respectively. The single false positive results occurred in a patient with a grade I vertebral artery injury.",
"     </li>",
"     <li>",
"      Another study screened 372 blunt trauma patients with 16-slice CT angiography identifying 271 normal studies [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/51\">",
"       51",
"      </a>",
"      ]. Arteriography was performed on a subset (82 patients) with normal CT angiography and identified 7 missed blunt cerebrovascular injuries. However, on re-review of the CT images, the injuries were evident in six of the seven patients; the seventh patient&rsquo;s abnormality was most likely not traumatic in origin. The inaccuracy of CT angiography appeared to be related, in part, to the radiologists&rsquo; experience, as all of the missed blunt cerebrovascular injury occurred in the first half of the study period.",
"     </li>",
"     <li>",
"      In a retrospective review of 7000 blunt trauma patients, 119 were screened using CT angiography using a 16-slice scanner and 92 of these patients underwent arteriography (3 refused consent, 24 were at high risk of contrast nephropathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/52\">",
"       52",
"      </a>",
"      ]. The sensitivity and specificity of CT angiography among the patients who underwent both studies was 74 and 84 percent, respectively. As with the study described above, the false negative studies were interpreted during the first half the study period indicating a learning curve on the part of the radiologists; the negative predictive value in the second half of the study was 100 percent.",
"     </li>",
"     <li>",
"      A study that screened 232 patients reported sensitivities of 29 percent for the 16-slice scanner and of 54 percent for 64-slice scanner [",
"      <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/15\">",
"       15",
"      </a>",
"      ]. The combined specificity was 97 percent. The major drawback with this study was a lack of quality control with no effort made to reconcile false positive results on CT imaging with the digital subtraction images; only the initial &ldquo;real-time&rdquo; interpretation was considered. Although it is important to acknowledge how things work in &ldquo;real time,&rdquo; a program of quality improvement is needed to overcome the learning curve associated with the interpretation of these injuries on CT angiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2918853\">",
"    <span class=\"h3\">",
"     Digital subtraction arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although four-vessel biplanar cerebral digital subtraction arteriography is the gold standard for the diagnosis of blunt cerebrovascular injury, CT angiography has largely supplanted its use. (See",
"    <a class=\"local\" href=\"#H19564062\">",
"     'CT angiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Arteriography is invasive and associated with access site complications (eg, hematoma, pseudoaneurysm), contrast nephropathy, contrast allergy, and stroke, and increased cost [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/6,54\">",
"     6,54",
"    </a>",
"    ]. In addition, arteriography is expensive and may not be uniformly available. As such, CT angiography is being used as the primary screening modality while arteriography is reserved for further evaluation if the results of CT angiography are equivocal, or are negative but the clinical suspicion remains high (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When arteriography is needed to obtain a definitive diagnosis, each of the four vessels (bilateral carotid, bilateral vertebral) should be imaged from their origins in the chest and cerebral arteriography included to identify the presence of occluded terminal vessels and evaluate collateral circulation to the brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564069\">",
"    <span class=\"h3\">",
"     MR angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies describe the use of magnetic resonance (MR) angiography to identify blunt cerebrovascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. The advantages of MR include the avoidance of iodinated contrast agents, lack of bony artifact, and earlier detection of cerebral infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H17#H17\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'CT versus MRI techniques in hyperacute stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, screening studies have found poor specificity at 67 percent with sensitivities ranging from 50 to 75 percent compared with conventional arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/35,50,61\">",
"     35,50,61",
"    </a>",
"    ]. Given issues such as the time required for the study and incompatibility with implanted devices, MR angiography is not used as an independent modality for screening blunt cerebrovascular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564076\">",
"    <span class=\"h3\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex ultrasonography was the first noninvasive study considered for the evaluation of blunt cerebrovascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/2,3,62\">",
"     2,3,62",
"    </a>",
"    ], and although it is the test of choice for evaluating other pathologies (eg, atherosclerosis) of the extracranial carotid arteries, the data do not support ultrasound as an appropriate screening modality for blunt cerebrovascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Duplex sonography is not a highly sensitive test to screen for blunt cerebrovascular injury primarily because imaging is limited to the cervical portions of the vessels; the majority of these injuries, particularly",
"    <span class=\"nowrap\">",
"     hyperextension/flexion",
"    </span>",
"    injuries, occur at the base of the skull [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/4,63-65\">",
"     4,63-65",
"    </a>",
"    ]. Although duplex ultrasound can provide indirect evidence of distal injuries (eg, obstructive waveforms proximal to a flow limiting lesion), indirect findings are not reliable when the degree of stenosis is less significant (ie, &lt;60 percent). Thus, grade I, grade III, and many grade II injuries could potentially be missed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H280052#H280052\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Injury grading'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients with skin abrasion and soft tissue swelling may not tolerate the examination due to pain. In addition, removal of the cervical collar is required to perform the examination. Given that these patients are at risk for cervical spine fracture, collar removal is often contraindicated.",
"   </p>",
"   <p>",
"    Duplex ultrasonography may have a limited role in evaluating select cases that involve direct blows to the anterior neck, follow-up of proximal lesions, and possibly in children, in whom other imaging techniques might require conscious sedation. When ultrasound is used, the ultrasonographer must be skilled and the interpreting clinician must recognize the limitations of the study in the trauma population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282373\">",
"    <span class=\"h2\">",
"     Choice of imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional arteriography has historically been used to diagnose blunt cerebrovascular injury; however, the use of noninvasive imaging predominates for the reasons defined in the sections above. Computed tomographic (CT) angiography (&ge;16 slice) is the most reliable noninvasive screening modality for blunt cerebrovascular injury. A relatively high false positive rate is reported in some series, and thus, follow-up arteriography may be warranted to definitively exclude an injury, or provide a diagnosis when a high clinical suspicion remains but the CT study is normal. (See",
"    <a class=\"local\" href=\"#H19564062\">",
"     'CT angiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As discussed above, the sensitivity for CT angiography for blunt cerebrovascular injury depends upon the number of scanner slices. Thus, the evaluation of blunt cerebrovascular injury at a given institution will depend upon the available resources; arteriography should be used if an appropriately sensitive CT scanner is not available. If arteriography and high quality CT scanning are not available, the patient should be transferred to a trauma center for further evaluation. (See",
"    <a class=\"local\" href=\"#H2918853\">",
"     'Digital subtraction arteriography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Duplex ultrasonography may play a role in the long-term follow-up of cervical carotid injuries; however, duplex ultrasound and magnetic resonance imaging are not sufficiently sensitive to be used for screening. (See",
"    <a class=\"local\" href=\"#H19564076\">",
"     'Duplex ultrasonography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19564069\">",
"     'MR angiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564083\">",
"    <span class=\"h2\">",
"     Injury grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grading the injury based upon its appearance on imaging was created to standardize clinical communication and guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/16/266/abstract/28\">",
"     28",
"    </a>",
"    ]. The treatment of blunt cerebrovascular also depends, in part, on the grade of injury. Injury grading is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H280052#H280052\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Injury grading'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219284334\">",
"    <span class=\"h2\">",
"     Follow-up imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of injuries evolve in a manner that could alter therapy and follow-up imaging is warranted in patients with blunt cerebrovascular injury (",
"    <a class=\"graphic graphic_algorithm graphicRef78174 \" href=\"UTD.htm?1/42/1698\">",
"     algorithm 1",
"    </a>",
"    ). The choice and timing of follow-up imaging is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link&amp;anchor=H259255#H259255\">",
"     \"Blunt cerebrovascular injury: Treatment and outcomes\", section on 'Follow-up for healing or progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3979752\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blunt carotid and vertebral artery injury are collectively termed blunt cerebrovascular injury and are rare but potentially disastrous injuries. The overall incidence of these injuries is about one percent of all blunt trauma admissions. (See",
"      <a class=\"local\" href=\"#H19563948\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The circulation to the brain originates from the carotid and vertebral arteries comprising the anterior and posterior circulations, respectively. The circle of Willis, which provides communication between the anterior and posterior circulation, is completely intact and symmetric in only about 20 percent of individuals. Because of the inconsistency, the neurologic presentation of patients with blunt cerebrovascular injury is highly variable. (See",
"      <a class=\"local\" href=\"#H19563955\">",
"       'Cerebrovascular anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients sustaining blunt trauma who have the following clinical symptoms or signs should undergo",
"      <span class=\"nowrap\">",
"       urgent/emergent",
"      </span>",
"      imaging to evaluate for cerebrovascular injury:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arterial hemorrhage from the neck, mouth, nose, or ear",
"     </li>",
"     <li>",
"      Expanding cervical hematoma",
"     </li>",
"     <li>",
"      Cervical bruit in patients &lt;50 years old",
"     </li>",
"     <li>",
"      Focal or lateralizing neurologic deficits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We screen for blunt cerebrovascular injury in asymptomatic patients who have the risk factors for blunt cerebrovascular injury listed below. We prefer to use computed tomography (&ge;16 slice) for screening. If an appropriately sensitive CT scanner is not available, arteriography should be performed. For institutions without this imaging capability, transfer to a trauma facility is indicated. (See",
"      <a class=\"local\" href=\"#H4011653\">",
"       'Indications for imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H282373\">",
"       'Choice of imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Injury mechanism compatible with severe cervical",
"      <span class=\"nowrap\">",
"       hyperextension/rotation",
"      </span>",
"      or hyperflexion",
"     </li>",
"     <li>",
"      LeFort II or LeFort III midface fractures",
"     </li>",
"     <li>",
"      Basilar skull fracture that involves the carotid canal",
"     </li>",
"     <li>",
"      Closed head injury consistent with diffuse axonal injury with Glasgow Coma Score &lt;6",
"     </li>",
"     <li>",
"      Cervical vertebral fracture, subluxation, or ligamentous injury at any level",
"     </li>",
"     <li>",
"      Near-hanging resulting in cerebral anoxia",
"     </li>",
"     <li>",
"      Clothesline-type injury or seat-belt abrasion associated with significant cervical pain, swelling or altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/1\">",
"      Biffl WL, Moore EE, Ryu RK, et al. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. Ann Surg 1998; 228:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/2\">",
"      Davis JW, Holbrook TL, Hoyt DB, et al. Blunt carotid artery dissection: incidence, associated injuries, screening, and treatment. J Trauma 1990; 30:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/3\">",
"      Martin RF, Eldrup-Jorgensen J, Clark DE, Bredenberg CE. Blunt trauma to the carotid arteries. J Vasc Surg 1991; 14:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/4\">",
"      Cogbill TH, Moore EE, Meissner M, et al. The spectrum of blunt injury to the carotid artery: a multicenter perspective. J Trauma 1994; 37:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/5\">",
"      Ramadan F, Rutledge R, Oller D, et al. Carotid artery trauma: a review of contemporary trauma center experiences. J Vasc Surg 1995; 21:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/6\">",
"      Biffl WL, Ray CE Jr, Moore EE, et al. Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography. Ann Surg 2002; 235:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/7\">",
"      Fabian TC, Patton JH Jr, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. Ann Surg 1996; 223:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/8\">",
"      Parikh AA, Luchette FA, Valente JF, et al. Blunt carotid artery injuries. J Am Coll Surg 1997; 185:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/9\">",
"      Berne JD, Norwood SH, McAuley CE, et al. The high morbidity of blunt cerebrovascular injury in an unscreened population: more evidence of the need for mandatory screening protocols. J Am Coll Surg 2001; 192:314.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.anatomyatlases.org/AnatomicVariants/Cardiovascular/Images0200/0292.shtml (Accessed on February 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/11\">",
"      Biffl WL, Moore EE, Elliott JP, et al. Blunt cerebrovascular injuries. Curr Probl Surg 1999; 36:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/12\">",
"      Cavdar S, Arisan E. Variations in the extracranial origin of the human vertebral artery. Acta Anat (Basel) 1989; 135:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/13\">",
"      Edwards NM, Fabian TC, Claridge JA, et al. Antithrombotic therapy and endovascular stents are effective treatment for blunt carotid injuries: results from longterm followup. J Am Coll Surg 2007; 204:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/14\">",
"      Eastman AL, Chason DP, Perez CL, et al. Computed tomographic angiography for the diagnosis of blunt cervical vascular injury: is it ready for primetime? J Trauma 2006; 60:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/15\">",
"      Goodwin RB, Beery PR 2nd, Dorbish RJ, et al. Computed tomographic angiography versus conventional angiography for the diagnosis of blunt cerebrovascular injury in trauma patients. J Trauma 2009; 67:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/16\">",
"      Crissey MM, Bernstein EF. Delayed presentation of carotid intimal tear following blunt craniocervical trauma. Surgery 1974; 75:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/17\">",
"      Zelenock GB, Kazmers A, Whitehouse WM Jr, et al. Extracranial internal carotid artery dissections: noniatrogenic traumatic lesions. Arch Surg 1982; 117:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/18\">",
"      Mikulaschek A, Hoyt DB. Intraoral blunt carotid injury in an adult: case report and review of the literature. J Trauma 1999; 47:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/19\">",
"      Carter DA, Mehelas TJ, Savolaine ER, Dougherty LS. Basal skull fracture with traumatic polycranial neuropathy and occluded left carotid artery: significance of fractures along the course of the carotid artery. J Trauma 1998; 44:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/20\">",
"      Bogousslavsky J, Despland PA, Regli F. Spontaneous carotid dissection with acute stroke. Arch Neurol 1987; 44:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/21\">",
"      Cook A, Osler T, Gaudet M, et al. Blunt cerebrovascular injury is poorly predicted by modeling with other injuries: analysis of NTDB data. J Trauma 2011; 71:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/22\">",
"      Franz RW, Willette PA, Wood MJ, et al. A systematic review and meta-analysis of diagnostic screening criteria for blunt cerebrovascular injuries. J Am Coll Surg 2012; 214:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/23\">",
"      Kopelman TR, Leeds S, Berardoni NE, et al. Incidence of blunt cerebrovascular injury in low-risk cervical spine fractures. Am J Surg 2011; 202:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/24\">",
"      Krajewski LP, Hertzer NR. Blunt carotid artery trauma: report of two cases and review of the literature. Ann Surg 1980; 191:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/25\">",
"      Perry MO, Snyder WH, Thal ER. Carotid artery injuries caused by blunt trauma. Ann Surg 1980; 192:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/26\">",
"      Fabian TC, George SM Jr, Croce MA, et al. Carotid artery trauma: management based on mechanism of injury. J Trauma 1990; 30:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/27\">",
"      Cothren CC, Biffl WL, Moore EE, et al. Treatment for blunt cerebrovascular injuries: equivalence of anticoagulation and antiplatelet agents. Arch Surg 2009; 144:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/28\">",
"      Biffl WL, Moore EE, Offner PJ, et al. Blunt carotid arterial injuries: implications of a new grading scale. J Trauma 1999; 47:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/29\">",
"      Batnitzky S, Price HI, Holden RW, Franken EA Jr. Cervical internal carotid artery injuries due to blunt trauma. AJNR Am J Neuroradiol 1983; 4:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/30\">",
"      Fakhry SM, Jaques PF, Proctor HJ. Cervical vessel injury after blunt trauma. J Vasc Surg 1988; 8:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/31\">",
"      Sturzenegger M. Headache and neck pain: the warning symptoms of vertebral artery dissection. Headache 1994; 34:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/32\">",
"      Sturzenegger M. Spontaneous internal carotid artery dissection: early diagnosis and management in 44 patients. J Neurol 1995; 242:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/33\">",
"      Kerwin AJ, Bynoe RP, Murray J, et al. Liberalized screening for blunt carotid and vertebral artery injuries is justified. J Trauma 2001; 51:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/34\">",
"      Cothren CC, Moore EE, Ray CE Jr, et al. Screening for blunt cerebrovascular injuries is cost-effective. Am J Surg 2005; 190:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/35\">",
"      Miller PR, Fabian TC, Croce MA, et al. Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes. Ann Surg 2002; 236:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/36\">",
"      Schneidereit NP, Simons R, Nicolaou S, et al. Utility of screening for blunt vascular neck injuries with computed tomographic angiography. J Trauma 2006; 60:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/37\">",
"      Berne JD, Reuland KS, Villarreal DH, et al. Sixteen-slice multi-detector computed tomographic angiography improves the accuracy of screening for blunt cerebrovascular injury. J Trauma 2006; 60:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/38\">",
"      Stein DM, Boswell S, Sliker CW, et al. Blunt cerebrovascular injuries: does treatment always matter? J Trauma 2009; 66:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/39\">",
"      Mayberry JC, Brown CV, Mullins RJ, Velmahos GC. Blunt carotid artery injury: the futility of aggressive screening and diagnosis. Arch Surg 2004; 139:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/40\">",
"      Carrillo EH, Osborne DL, Spain DA, et al. Blunt carotid artery injuries: difficulties with the diagnosis prior to neurologic event. J Trauma 1999; 46:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/41\">",
"      Prall JA, Brega KE, Coldwell DM, Breeze RE. Incidence of unsuspected blunt carotid artery injury. Neurosurgery 1998; 42:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/42\">",
"      Biffl WL, Moore EE, Offner PJ, et al. Optimizing screening for blunt cerebrovascular injuries. Am J Surg 1999; 178:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/43\">",
"      Biffl WL, Moore EE, Elliott JP, et al. The devastating potential of blunt vertebral arterial injuries. Ann Surg 2000; 231:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/44\">",
"      Cothren CC, Moore EE, Biffl WL, et al. Cervical spine fracture patterns predictive of blunt vertebral artery injury. J Trauma 2003; 55:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/45\">",
"      Ringer AJ, Matern E, Parikh S, Levine NB. Screening for blunt cerebrovascular injury: selection criteria for use of angiography. J Neurosurg 2010; 112:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/46\">",
"      Biffl WL, Egglin T, Benedetto B, et al. Sixteen-slice computed tomographic angiography is a reliable noninvasive screening test for clinically significant blunt cerebrovascular injuries. J Trauma 2006; 60:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/47\">",
"      Biffl WL, Cothren CC, Moore EE, et al. Western Trauma Association critical decisions in trauma: screening for and treatment of blunt cerebrovascular injuries. J Trauma 2009; 67:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/48\">",
"      Bromberg WJ, Collier BC, Diebel LN, et al. Blunt cerebrovascular injury practice management guidelines: the Eastern Association for the Surgery of Trauma. J Trauma 2010; 68:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/49\">",
"      Bub LD, Hollingworth W, Jarvik JG, Hallam DK. Screening for blunt cerebrovascular injury: evaluating the accuracy of multidetector computed tomographic angiography. J Trauma 2005; 59:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/50\">",
"      Biffl WL, Ray CE Jr, Moore EE, et al. Noninvasive diagnosis of blunt cerebrovascular injuries: a preliminary report. J Trauma 2002; 53:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/51\">",
"      Utter GH, Hollingworth W, Hallam DK, et al. Sixteen-slice CT angiography in patients with suspected blunt carotid and vertebral artery injuries. J Am Coll Surg 2006; 203:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/52\">",
"      Malhotra AK, Camacho M, Ivatury RR, et al. Computed tomographic angiography for the diagnosis of blunt carotid/vertebral artery injury: a note of caution. Ann Surg 2007; 246:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/53\">",
"      Sliker CW, Shanmuganathan K, Mirvis SE. Diagnosis of blunt cerebrovascular injuries with 16-MDCT: accuracy of whole-body MDCT compared with neck MDCT angiography. AJR Am J Roentgenol 2008; 190:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/54\">",
"      Wang AC, Charters MA, Thawani JP, et al. Evaluating the use and utility of noninvasive angiography in diagnosing traumatic blunt cerebrovascular injury. J Trauma Acute Care Surg 2012; 72:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/55\">",
"      Friedman D, Flanders A, Thomas C, Millar W. Vertebral artery injury after acute cervical spine trauma: rate of occurrence as detected by MR angiography and assessment of clinical consequences. AJR Am J Roentgenol 1995; 164:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/56\">",
"      Giacobetti FB, Vaccaro AR, Bos-Giacobetti MA, et al. Vertebral artery occlusion associated with cervical spine trauma. A prospective analysis. Spine (Phila Pa 1976) 1997; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/57\">",
"      Weller SJ, Rossitch E Jr, Malek AM. Detection of vertebral artery injury after cervical spine trauma using magnetic resonance angiography. J Trauma 1999; 46:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/58\">",
"      Bok AP, Peter JC. Carotid and vertebral artery occlusion after blunt cervical injury: the role of MR angiography in early diagnosis. J Trauma 1996; 40:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/59\">",
"      Hughes KM, Collier B, Greene KA, Kurek S. Traumatic carotid artery dissection: a significant incidental finding. Am Surg 2000; 66:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/60\">",
"      Punjabi AP, Simon J, Plaisier B. Blunt carotid injury. J Trauma 1996; 41:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/61\">",
"      L&eacute;vy C, Laissy JP, Raveau V, et al. Carotid and vertebral artery dissections: three-dimensional time-of-flight MR angiography and MR imaging versus conventional angiography. Radiology 1994; 190:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/62\">",
"      Fry WR, Dort JA, Smith RS, et al. Duplex scanning replaces arteriography and operative exploration in the diagnosis of potential cervical vascular injury. Am J Surg 1994; 168:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/63\">",
"      Mutze S, Rademacher G, Matthes G, et al. Blunt cerebrovascular injury in patients with blunt multiple trauma: diagnostic accuracy of duplex Doppler US and early CT angiography. Radiology 2005; 237:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/64\">",
"      Landwehr P, Schulte O, Voshage G. Ultrasound examination of carotid and vertebral arteries. Eur Radiol 2001; 11:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/16/266/abstract/65\">",
"      Sturzenegger M, Mattle HP, Rivoir A, et al. Ultrasound findings in spontaneous extracranial vertebral artery dissection. Stroke 1993; 24:1910.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15154 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_266=[""].join("\n");
var outline_f0_16_266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3979752\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19563948\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19563955\">",
"      CEREBROVASCULAR ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3979546\">",
"      Anterior circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2918748\">",
"      - Internal carotid artery segments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3979568\">",
"      Posterior circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2918703\">",
"      - Vertebral segments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182474602\">",
"      Site of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H219286045\">",
"      MECHANISMS OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3981270\">",
"      TRAUMA EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H219286132\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3979590\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19564013\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282468\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4011653\">",
"      INDICATIONS FOR IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3987108\">",
"      IMAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282240\">",
"      Imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19564062\">",
"      - CT angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2918853\">",
"      - Digital subtraction arteriography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19564069\">",
"      - MR angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19564076\">",
"      - Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282373\">",
"      Choice of imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19564083\">",
"      Injury grading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H219284334\">",
"      Follow-up imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3979752\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15154|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/42/1698\" title=\"algorithm 1\">",
"      Blunt cerebrovascular injury algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15154|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/4/2122\" title=\"figure 1\">",
"      Cerebral arterial circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/61/32728\" title=\"figure 2\">",
"      External carotid artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/46/32487\" title=\"figure 3\">",
"      Collateral circulation between external and internal carotid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/48/4874\" title=\"figure 4\">",
"      Lateral view of the internal carotid artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/0/36867\" title=\"figure 5\">",
"      Segments of the vertebral artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/17/26899\" title=\"figure 6\">",
"      Mechanism of blunt cerebrovascular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/57/2966\" title=\"figure 7\">",
"      LeFort fractures of the midface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=related_link\">",
"      Blunt cerebrovascular injury: Treatment and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=related_link\">",
"      Facial trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2026?source=related_link\">",
"      Penetrating neck injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_16_267="Thallium 201 protocols";
var content_f0_16_267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thallium-201 protocols for viability detection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Stress - 4 hour redistribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Stress - 4 hour redistribution, late-delayed imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Stress - 4 hour redistribution, rest reinjection and immediate imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Rest - 4 hour redistribution",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_267=[""].join("\n");
var outline_f0_16_267=null;
var title_f0_16_268="Cancers associated with hypercalcemia";
var content_f0_16_268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malignancies associated with hypercalcemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Osteolytic metastases:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Humoral hypercalcemia (PTHrP):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell carcinomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal carcinomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CML",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1,25-dihydroxyvitamin D:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma (Non-Hodgkin, Hodgkin, lymphomatosis/granulomatosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian dysgerminomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ectopic PTH sectretion:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung carcinomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroectodermal tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid papillary carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic cancer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_268=[""].join("\n");
var outline_f0_16_268=null;
var title_f0_16_269="Prevalence of UTI in febrile infants and children";
var content_f0_16_269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of urinary tract infection in febrile* infants and children by demographic group",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Demographic group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence or pretest probability (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        0 to 24 months",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        7.0 percent (5.5-8.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        7.3 percent (5.0-9.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White girls with temperature &ge;39&deg;C",
"       </td>",
"       <td>",
"        16 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        8.0 (5.5-10.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White children",
"       </td>",
"       <td>",
"        8.0 percent (5.1-11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Black children",
"       </td>",
"       <td>",
"        4.7 percent (2.1-7.3)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        0 to 3 months",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        7.2 percent (5.8-8.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        7.5 percent (5.1-10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Circumcised boys",
"       </td>",
"       <td>",
"        2.4 percent (1.4-3.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uncircumcised boys",
"       </td>",
"       <td>",
"        20.1 percent (16.8-23.4)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        3 to 6 months",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6.6 percent (1.7-11.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        5.7 percent (2.3-9.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        3.3 percent (1.3-5.3)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        6 to 12 months",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        5.4 percent (3.4-7.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        8.3 percent (3.9-12.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Boys",
"       </td>",
"       <td>",
"        1.7 percent (0.5-2.9)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        12 to 24 months",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4.5 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Girls",
"       </td>",
"       <td>",
"        2.1 percent (1.2-3.6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Circumcised boys &gt;1 year",
"       </td>",
"       <td>",
"        &lt;1 percent",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        &lt;19 years with urinary symptoms and/or fever",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        7.8 percent (6.6-8.9)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Temperature &ge;38&deg;C.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      95% confidence interval not available.",
"      <br>",
"       &Delta; Most of these children were older than two years.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of Urinary Tract Infection in Childhood: A Meta-Analysis. Pediatr Infect Dis J 2008; 27:302.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_269=[""].join("\n");
var outline_f0_16_269=null;
var title_f0_16_270="Exercise testing in IPF";
var content_f0_16_270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exercise testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exercise test in a woman who presented for evaluation of dyspnea on running and a dry cough of 18 months duration. She did not smoke or have a history of lung disease. The chest x-ray and lung function tests were normal. Her resting room air arterial blood gases (elevation 5000 feet) revealed PO2: 78; PCO2: 34; pH: 7.43; Sat: 94 percent; AaO2: 3.8. The patient performed an exercise test on a cycle ergometer. The work rate was increased 10 watts per minute to her symptom limited maximum. Blood was sampled every minute from an indwelling catheter. Her resting and exercise ECG was normal. The patient achieved 94 watts (65 percent of predicted workload). The PO2 decreased, AaO2 increased, and minute ventilation (Ve) increased systematically with increasing work rate (shown as the percent of predicted maximal VO2). The study was stopped because of mild shortness of breath and leg fatigue. Lung biopsy revealed UIP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_270=[""].join("\n");
var outline_f0_16_270=null;
var title_f0_16_271="Bonney forceps";
var content_f0_16_271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bonney forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 144px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACQAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKvGvivxx/wALTi8I+B4vDf8AyBhqskusLP8A892iKgxn/cOMevPQUf8AF7/+qbf+T1H/ADdP/wByZ/7fV6rQB5V/xe//AKpt/wCT1H/F7/8Aqm3/AJPV6TrGqWejabNf6lN5NrFgMwUuSWIVVVVBLMWIAUAkkgAEmvLNU+Mt3baxpFla+BdeKarcS2tm168VnJNJGRuxHI2QOeC+3PTrnABa/wCL3/8AVNv/ACeo/wCL3/8AVNv/ACertvB3ivTvFmlxXmnLdQO0STNa3kDQTxq+dpKN1UlWAdcqSrYJwa36APKvBXivxx/wtOXwj44i8N/8gY6rHLo6z/8APdYgpMh/3zjHpz1Feq15V/zdP/3Jn/t9XqtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5V/wA3T/8Acmf+31eq15V/zdP/ANyZ/wC31eq0Acx458J2niuLTUv9U1OxhsrpLpFs51iEsqkGPflTnawBA45x14rj/iH4WtfGviW21iDV5BfeEpS1hZxRAh7xRHO4fPMilRCu1CMHdznIG94wsBqviNZr47rHw/apqsMUTAyNdF32vt5+6kUijI581scqCKusRaVDqVvrthDprW2iTI8V0lySsT3sytds6qwUHypEkDNn/WZxjkgDNJ8Nrr3xRl8exancxwWkH9lWkEBHk3kIDM7uedy+ZIdoGMGIHnPHo1chpmg2ui+ILefS7MWluNumRQwMVgS2WN5eIwQobzSctgtxj1J6+gDyr/m6f/uTP/b6vVa8q/5un/7kz/2+r1WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8q/wCbp/8AuTP/AG+r1WvKv+bp/wDuTP8A2+r1WgDzX4m6pq3gfVl8aWGmtqujC1Sz1i3hIWeGJJC6XCDHzhBJKCpIxuByBuI5DQ9R8KWPw61r4baVremT6/d6fqDQRWhVknM7TeWEZflL7WTCZ3bcdhXu00Uc0LxTIskUilXRxkMDwQR3FcRL8Ivh/LeNct4R0gSMckLAFToBwg+UdOw9fU0AZnw0vUubbRtF8M28Uvh7QoVim1ZCRHdTrG0bpENoEh3lmaQErnpksdvptQ2Vpb2NpDa2NvFbWsKCOKGFAiIo4Cqo4AHoKmoA8q/5un/7kz/2+r1WvKv+bp/+5M/9vq9VoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBA2SRg8e1LRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcB41+F9j4q8VReIf+Eg8SaNqUdkLDfo96tvuiDs+CdhJ+ZvXHA44rJ/4U3/1Uf4k/+Dz/AOwrkv2mviR4w8EXlmvhV4rewaAJc3LxRy7ZpGYxgBs4O2GTqCCGPcDHnmieKf2idbsbe70wX0trPCs8UzafaRrIjH5WBZBnOMj2IPQg0Ae4f8Kb/wCqj/En/wAHn/2FH/Cm/wDqo/xJ/wDB5/8AYV43PY/tK3bvve9UyrzsuLGIAEY4ww2n6YIrO/4RL9otok/0rXMbdoH9tQg4znJ/e9ffr26UAe6/8Kb/AOqj/En/AMHn/wBhR/wpv/qo/wASf/B5/wDYV4O/gf8AaHljZmvtfBLD5Rr8angdeJsAfz9Kjf4f/tBhEcah4gZm6qviJQV+v77H5E0AfSXgr4X2PhXxVL4h/wCEg8SazqUlkbDfrF6txtiLq+AdgI+ZfXHJ45rv6+LoPhn8e5iJpNS1mGVE2r5niDLYznaCspxyB3pYPhB8br2VpLrVLyGTywm+41ssSo6LlWbj26UAfaFFfHEP7PHxScR3DeI9PinUZUNqVxvXPUAhCP1qM/syfEQurnxBoZdejG9uMjjH/PL04oA+y6bJIkaF5HVFHVmOAK+Lbn9lvx45klfVPD88p+Y/6VMWc/UxdfrQv7K3jgqP+Jp4cGeSDcz/APxmgD7UJA68VjyeKNAjgnmk1zSkhg3CV2u4wse0kNuOeMEEHPQg18ZeJP2bPGHh/wAP6lrF5qOgyW1hbSXUqQTTM5VFLHaDEBnA7kV6o2hC4+Kunf2VbfDebwjcXdqFs4ILFrhkNsWZk+XcRuDEYJbG0gbd1AHti+PvBzH5fFnh88Z41KHpjOfvegP5U6Tx14RjWVpPFOgoImCyFtQhGwnoD83Br588KaX4huPDOo3Vx4R+Gt/q32ixispEt7FoULvJ5vmmNx8wHl4C5J3fKGOca974c8TLaeG3Pwe8EyecqnVzHZW/7g/aCAItspY/uwrHAYfN7FQAe2x+OfCcmzy/FGhPvwV26hCd2TtGPm5yeB71oWevaPe3MtvZ6rYXFxEFaSKK5R2QN90kA5GcHHrXz7qWkR2epeKbLUvgnp93aWMVxc6dNYWZQ3iG7RY0DRh/nKHf2IUMAqqTWdr+g+Ho/Cvhy7l+B9+82pTXhvba3lukk03bKg3OyR7mVgNyggAAMF4JoA+mF1bTWkto11CzaS5yYFEyky467Rn5se1PbUbJL9LF7y2W9dSy25lUSMB1IXOSK+cfEekeEm8T+J9I/wCFVT2lvYWOozwatbBoluH+zjcsSmMpu5+T7wRgGUfMa4m/s/A0XgpdRl+G2vW6tqd0DpounEsSR2kZaQyNH5gjUtvwTgNuJJX5QAfZUE8NwrNBLHKqsUJRgwDA4I47g9qkr5e8MeGfAEfxU0jTF8Lawd1tAsN/MYzZyH+zi5WRVVQSyEuW+80ikjA3CuHtbD4SJ4CutVtpfGNnBHqltBOzpbte4aGYqsTAhUjfl2JzkxgY6EAH2zRXyRpnhvwUnjjwdBa+MNXsb3ULTTbg26W1wBqJYbmaSRZSUeQ46HbHjv1pvhvS/D954O8S3sPxg1a7ayezjXVZYL6A6aJJWB2x+aA/mYAyc7dpJx1oA+uaK+YLLRo5NZ8Ix2nxQvVs76CyuJkN/qEcmqFriSNzgv8AuvNXYg5zuj4AGTVODTL6a98Sqnxa8xLOPds/4Sa8t1s/9OUfNKwYZMP7sEhsO4+VuGoA+q6K+XX8Oa8mkeEET4oxy3t1KRdXMfjGZU1BPtEislsrBtz7WjXcMBWQjDE5qG/i+IWm674wOj+PIp7SxjuZdPtl1y3ne32XSRqlyLg5UCJ3JYnIZVy27AIB9UUV8vX8vxltfDejNpPiV77V7qe5E6LPp0kL+XIojMLMAWyu/KAk5XkDOK6e8h+LtrrXi0vrGsvodnp93No8sdnp7zXNxHt8pHRYmYq3zdFUnHagD3qivk7V9d+PFlpRuILzXZrsXtxbi1/4R6AsYo1iZJSURlG7zGGASMoQCxBrVbXvjLpfijxDp8+qX13p+nWM11b38/h1ViupI4fM8pdgABY5UHc3TgdqAPpyivE/hF4i+I3ifw/qupeI9R0rRJ7G7NtNaajokgaJVijl3k+fGVBWQH5geADnmo/DPxX8U6qYbh9E02XT7zb9iZJGillDqxjJG50DEhU2Bz8zP82IJtgB7hRXCaV45n1S9S1sINJuJWUOZFvZ1hwThAJDb4YuAXUD7yYcZVlJzbf4geI5HRpvDGlQ2rySkXLa06xi2jGXu2LW4CwZ4Vjgt95QV+agD02iuK03xTr98s5Tw1bERruzHqqHGU3qHBQMhYFSAR0bJxRaeMtWe2spr3wdqluLvAiU3loGLEEhcPKpyQOBjPqFwaAO1orj5/GV9bAm68Ga/Aio0rNJc6cAqLjc5/0rOBkZx61GPHjbplbwn4qBhcRyYs0baSu7I2yHcMEfdzgnHXigDtKK5i58b6VaoXuLXX0UZyRoV6wAABJJWIgDnqfQ1FB4/wBFuIklgt/EMkUihkdfD2oFWBGQQfI5HvQB1lFcWnxN8LyaTLqkU+pyabEjyPdR6PeNEqqSGbcIsYXBye2Dmr8XjXS5GIW18QAhd/zaBfrx+MPX260AdLRXNDxrpXlPJ9m18Kp24Og3wYn2Xycn8BTl8ZaSUDNHq6A5wJNHvEPHsYgaAOjornj4w0kZ41PjPTS7r/43TD410YYydSGfXS7r/wCN0AdJRXOR+M9HlYrF/abspwwXS7okfXEfHWpbTxfoVykjf2gkAjO1hdo1sQcZ6SBSaAN6iobO6t760hurKeK4tZkEkU0Th0kUjIZWHBBHcVNQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5z8SPh5qXi66nFj4jXTNNvYoIdRsmsvOF2sTswUyCRHRW34YKQSB1GTnUg0nxtZ2cdvZ674XWOJQkUf9gzIqqOijF3wAOBx2rsqKAPN7+P4vI7CwuvAM6Y+Uz215ESdx6gSNjjB+pI7ZNm0n+Kaowu9O8Eyvu4MV/dRgD0IMLZPvXf0UAcPNrnj6KTaPBWkTqDgvFr5wRgcgNbg+o5x0/GprTxP4lCH+0vAWqI/b7Ff2cy++S8sZ+nB/CuyooA46Tx2ltdmDUfDPiq1wobzF0xrpOc4Gbcyc8c+nGaqQ+PNT1R2j8PeCPEU7oyh5dTiXTYVBJ5zKd7HjPyoeoyRXeUUAcSPFPilYJDJ8PtTMwYhFi1GzZWGTg7mlUjPHbvUM/xCubKWSLUfA3jCGVITN+5s4rpHP9xWhkcFj6HHTtxXeUUAeewfFvw6iRPrltrvh9ZJEiV9Y0qe3jDMQAGk2lFAJwSzAD1xzXR2fi/Q9TlSPRNX0rVJGDHZa30TtgD0Dc8kD2yK36p3ulaffZ+22Fpc56+dCr/zFAHN+MX1LV/DGqaWnh28niv7Ka2kCXUCNh4yvy5fH8RGSR0zXnfw5+Dtv4d1Tw7f3PhLSxe2kFu82pHW7lp0nEI8w+RtMRxJkABsYAPsPVJ/BXheff5nh3SNzkFmWzjViR0O4DOfeuX1TT/h5pLvDqPiIabIJd5V/E9xbsr4IwP34IGM/KOPagDyDT/DWiQfD7V3HwvuZIJ7y0MmmaX4jGoS3Cxh/wB6DGSwC+byq9d4PCjNbOj/AA70rV4fBuozeC/GMQ0+2tbeB5rm3iktmjupHYSRPsYjLEs23lSu0Dlq6TUfEnw7sEeOL4n3kQUdtSXUhjvgTJMCe3c+nU55+31PwLdSwy6T4w1udrqRkQwaHPGLh1XccG1gh3MoGcg5AHPegDA1bS/DGn3HxBvru0+KOnxSxs2oTz20SxOGv4nxbtwNxYsVLZ+Rnb63tX8SeFrHwX8O2PiP4i6Lol19rFpJDOkczD7QuDcybipRRnYAGOw5PodLWfirJ4c0C/XSbvU3jjiEqSXsEcssbEqgUNNdmQruxklH27ieQKyIP2gvFVroTXGueBrv7NEY4rq8ckRxlgp+dfLGwMHUqGPIYYJFAFs+KNOu/iF45WD4la9G0NpqINv9nka0slWNB5kWJfmZDvxgDcRxt4LYWr+KUXwDZiw+NN4IpNQu/K1G40+7WaQpBCFtztBIVS4LP6yAgEgiuvs/2g9Nult7i30TUY7R4yBAtjBI4jC8hW+0rkA4/gAxx15qq3x+8HPp9vH9j0KXzI2aeGaO4iCSMuGGBbOCD0znkdQKANzQPEmqt8T9O01/iVp94HtIpZ9Fex8syL9gDecsxj4Jk/elMjCHP+zWFYeJvFt54Jvr2x+KPg+5u01OCGHVr5Es4kTyWZ4SGhwWJPGMnaGORyKmtPjR8Of7VTUpdC0eTUYx5cd5ZpH5oTy9mFedIWHy/Jg4GOORVC48ZfA/VdCl0/UNCSw00TLcvbxGOPMqIUVsW8pLHa7dM9++KAN3TrbXJfGfhaOC++H15pkNrprXNnH5BnaRYWPn24CAgAM5jwQNv3QAWqh4d0LxJL4G10R+DvhxJc3X9nvDbWIX7I6K7s7XIEmG2D5gQTnJ+8OK6HR9L+FF/q+n6/pLtPd6WLe3tbi3lnlEKwLsRAFyCMDBJzn1zzWUPAfwmt9BuNBjfVtLtb5raa586O5ha4MLOFLGZMLkuwbbt9ttAEbeCNePiXwDdTfDzRJE06CzW6uo750OnstyzssK+d8yoCH5DZ3EZI4rKg8I3bR+LjefCBWjvYxFbpDq8sbahm+Rj5p8w7CDtk3ELhYyMhTxtR+B/hdeeIvC99D45he88Mw28FrAuqWuSIJmkHmjbkks2Djb+dWdP+Dfha7j8R29r4uubmbXyv28W8sAwwuFn/dKq/J0YY5A3ZxxigDAg0e2ji+Hqt8J9biFlcs6Kt/M/wDYx+38kgpiYHiT5v4O+BurO8Q2vhrS9f8AHesah4R8a6EqpLLNq1nLgXjf2lCwlhMgwjb1jddpGE3EDOGPoUXwZuYT4UaLxdqG7w6262DxkiYfavOCzAONw2Yj4xnAbp8tRX3wq8XDUvEN1p3xC1JP7ZjdQjPMq2LNdxyboQJD92ESIBkHJ6gMQADyPxZbfDL/AIQ3w1YTW/jewtlkvPJQ21u0toxuUV/PDnKgOAo2nOMBiTxXSPN4IT4kfFKdNR12G9GiajDqw8iAxYMkQJt2Vgd4J2gOMknkrjnrJfh18UIdH0y3sfH+66015cSSyyk36tOHXzmYNtITI6Pj7vI5rXl0j4qW/iDxU41bT77SL+3ul0i3cR/6FMXTyXkzHkgLv+UbxwMjnNAHhF3c+G4/AunHSPiX4o0zSzqt/wCU8lmzzFfLtQY32zLuC5U5A581vlG0mvQbu7tz8UvHQt/iXqFuy6ZeNcWLw3KJZ4twBPEVYhzH97gK3Hyg9am13TvjZB4btIE07RdZ1hbu7F3deVaFZYSkIjZQ+wc5lU/KCQgyOmdLxBb+NbzxJ4rjn8D6ZN4fuLC+SyuFt0W5nkNuNqSNHL5mHKBDjG4EA9sADPAU/k/Ab4hXlp4suPFieXfSQ6pcxTxyNtsk+Rlm5+VgehYYxznIDbnR4LOCzlhhQ2E1s6WMd1bTXDLYJBGq7otoO0oyBlzu24hUGW4metX4X6DrF98D/EnhzUPDUHhe+nF7ZQ2sfmeW3mRcSDzHc4LOR94j5eMVV+Ftx/b+gaVoTQ3rnQrBLa+ka7hW4S5jBV42Rf3qMjFkhJKj/Wv1SJmANO4sTfFf7Wt9WuIJJDbtblk8+6kdF3xfJhXdgD50oKxxKhhj+XzTSwS3+rX8cSX8FxNMv2ppJYV8lvLkyLvBORaxbdsC8GV8yHK5lrsF8HQy2d1LdopvriJI2t4Z2jt44kHy2qEDKwkgb8AF+dw24QTnw9bx3kSXlzJO15P9oukERIupFX5Q3UJCgC4XgZC5LFjvAMS31Ke103doLwx6a8DzRTTqGZgzbpL+buwJyURRmRm5KqSySW8csmoabealDNHcK5gsBKwkktVdV3Fl/iuZBuJIyI4w3Kjd5nYNLBa3D28cc5kdGuHcRu+Bk/xEEE5OFTOcdBgVzSaTcSCebVNLmu7xYo7e2T7UTEsLSn92ZCxcnCo0zEfOMKPMAxQBz+p6auqeIZtSjgu7+NnWaGaWTfHJHE+4SeWg5ii3HykAJml+ZhhFlGvHqOoaBYWmm6XpFxPIk+GhLvO/7wsyrJMxx5jZMsj5YIufvlk39JqVleXlyZbd/IEbKiq20B+VzKThtxQbtikY3ckH5Supa26WtukMQO1R1JyWPUknuScknuTQBnXNw2nPDNdXAHnvsFtvDNLMwGEjLYGAFY4wM8scYOaOuNNZaZdrLc3komkZpprRwssQYhY4olw3zN8iDG3qz7lbGdyGMTGOe5giE8Zfy2+8UUnAwSAQSuMj145xmpyoJBIBI6HHSgDmW017dbRLmVf7Js5FMFlb24XLBgIEABPyxgKevLjd8qrtrRb/AIl9226a7ubvUJsIoBZIVC9dudqIo6txuYgckqtO0lrq9aebVdJispba5litD5yzM8IO1ZcgDYXAztySBjJzkCHw7Pf3z3N3qely2AZsW6XMkTTKnQqRHlVUlQw+dySxztwAAC7FLHYtZWDy3FxPIrYkcbmbaPmdyAAOSPQZYAD0tySJFG8krqkaAszMcBQOpJrC0B9abU9TbVbC3gtzO6wzC4DM0akCPCheFK5Y7myHLADGDTvEWlX2q6jpMaXEUejwytNfQneJLggDykBUgbN2Syn72FByu4EA3ao3t+0N7a2dvA89xMdzY4SKMEbnZu3XAHJYngYDFb1Y/h3R5NKhvmuLs3d9e3Ul1NcbCuSxwihSxwEjVEAHXZk8kkgFiDWLK41m50u3m828tUV7hUBYQ7sFVdugYg7gp5xzjBBOhWZ4a0eHQNEtdNglln8lf3k8zbpJ5CcvI57szEsT6ms1U1fTtMuL+7t11fXpWPk2tu3lwxZ4WNXb7qADLyEFmOSF+5GADn9e0KbR59T8RfDdrf8AtSO5afVdIWTMGptsBdCBnybgqQyuoG5iN4YNkdvoWrWOvaNZ6rpNwtxY3kSzQyrxuUj0PIPYg8g5BqlotpH4d0GefVbm3ExMl9qN39yMyH5nbLEkIoG1dxJVEUZOK8p/ZAvJr34YX8s2Ap1i4McajCxqUjYqo7DczH8aAPcaKKKACiiigAooooAKKKKACiiigAooooA87n+JbfbHbT/Dmo6npeP3U9nPA08o80x+cIGdSLfIOJiQO+NuGOHP8aJZLN73TPCd7NYrbtc77i8hicqttHdHCKXz+6mjbr1JHUVm6H4O8ReAPF17/ZGgNrOkzJi11e0kthqFtEBhbSQTsoeJdqBQpXCqOeiilpPh63i0C50TUNK8b25mtY7NpF06M8fZLa2yCjyL0tQx5wN+DQB19v8AEvU7vXZtMg0TTo2jkKeZJqLk8ag9jkKIOfmTdjcOCB7jlbz4u+KjbwXdvp+hQWkun/b18wzTN/x4PeeWfuAcKq7snGc4PArbs9H0u11q41H7J4q8+STftOlsUAGoSXxAwpzl5NvXoo71z0nhbQY7BLSeXxmYks3s0UeHbl8I2npZFhtiODtTf16nGMZoAvN8QfG66z9gN14bONRksDINLn/gvbO13Y+09T9s347bMZO7Ioav4v8AHUVxalvEVnEtzFFOFt9JVVRXhv5Nvzu5JBslGc9HPBxzpjSvDn9sSakbjxi0r3rXojfw1fFV3XtvdleLcH71sq5z0PciotW0/QbhrV2vvFMKwQRW5L+F7852QXkIIPkjGftmcf8ATPH8WQAc9c+IfFT6FeXV74y1tpba2WYeRDawjebbT5Oiw5I3Xsny56BR1GTJceNPEXhS08R6+2uanqtpohRv7PvREEuUbVLqz2swjDowigRgwP38kgglTZOn+H/7Je1k8Q6tG01uITPJ4XvEHmJDYR71ymAQbINjP/LXGfl5o48NQRXFtB4ztZbF/Llurjy7i3mt5Yr+e8iKIqkOSbhkIYjaUVsMflAB3ngnxH4s+ItpHdpL/wAItbi3VpI4I47mUSGRhgtIOCUAONmFyPmYllTtpdBvppfKn1/WZrZkO4iSGEqdykYMcSt2Pcde+eOc0L4l/DvTbOLTbXxHZ20VuBGiXW6EquTgZdVJx6nJ7sSck7X/AAsbwWZVCeMfDRUg5H9pw5zxjHzfWgDQTw1a7VEt7rEpXGCdTnXsRztcZ69++D2qy+h2T26QyG8kjTGA97M2cHPJL5PTvWNdePPC0iRLZeLvD3nyMhUfb4W3qWAOBvHbIB7HHB6GzpPiPwtFZi30/X9IkhgJQ7L2JtpzyCQevPOefXmgBJfAnhSd3e78O6VdyOSWe6tknYkjB5cE8itTStF0rSLd7fSdMsbG3k+/FbW6RK3GOQoAPFVpdf0+ZoFsNX0lmaRQ264Vsp3CgH7x6D8+ehszXg+yk2d3ZyS4KJ5r/K0h+7kg8cg8AfTGKAMqbwN4bkUImi6ZDD5izNFHZQ7WlVdschyh+ZBkKRjGT1qzD4T0OCMx2umWtrGQ4ZbWMQBg/wB4HYBkE8nPfnsK21YNyrAr7VHMZd8axBcZy7MMjHoOep/Lg+1AGFeeHtNtzb3cNswktXypE8isoYbSVO8YzkbjzuC4wTjHnHxJ8M+E3uGe50vUjqsKl/Mi003QuH2jaJbiaCWN22KwG/cFBxwdtetapNqEaoum2kc0hPzNNJsRV4yRjJLc5A4B2kFl4J8/8f8AhTU/E2p26aho9vq2lWge6w94YjI5B2wLBgoTtXYZHYHMpIYKGQgHiepabbxQxTPBqtnZrNbtfR6j4WsHkiz+7eYr9n5UK0fyn5gTwHL5TnNbuJLye2tI9N1GWGOaQJbHw1pyTw/vGEcTqsOFbaqlhnBLDgdvVvEHgvxl4hg1KK98JxRBs2tsra7uibG3Fy6hTuK4/dZUEZcupJyePb4ZePbu3uodW8LXUtxNNJOtza+IVgRbmQsjzshVt3y4PY7cjJLYAB5zqOgyXtvLPL54htLb7QZE8N2tskltzsmVoz+8BDAseoHALkCrejeBL3xNpkBsYLO70K3mDXF9plpH50D7MMsqBTcYBA4CMuPmAJzXpmr/AA/8U3Ws2l0nhiKK1a3uTHHaareLKkrrHETPK0WWUgPtQAfJuUtt2g5f/CsfFmp6rEbzwIyWMSNCbhdUEtyqkKrGNZZEjOSXcKVVdrbT0wQDlo/ANjqlt4c0e5vrbTJ5oXacJpbNdfbNryOshaOMiNQyJtQuBwThcPXG3uh2yatdT6TrUNozTsnnQMsVtGXkcKu/zCVQKhPV8jBG4ZYfSHh3wTqWm/Z518A6rbTRySuksGpWckx+dfLMgMiZbZuG4SbkP97Oax4PBHiCa5X7T4T1+0jkjuIpRDLBN5sck5mSJwbxEZFLvnK7WzkrnkAHjPh+4Z1SK4+IPiC0t7t/tMyQSxkNIxYOzg3QIYhUyxUnkkgKoLenwfDmz8U6Y92PE/i/UbbUInihW6274dkhUM8blmdd+SIxtbpyCcjo9O0DxfpEsl1ZeF9YF8jPDDezJDcy8xOgmdZL5laRQURWxhU3KS4wtTeL1+JE2vPeReH7KWU2wVY7jUPKaLKglBsvkDRmQyfMV3cLxhVCgHmmrfCnxBo96Y9B1r+z7eJ2KfaBdyzKp+6GaO0AUhQAVBIyCRkYq9A/xG0kR2jfE/RUV4XuCtxJcr5ca43Mxe3BUjjgndls45zXVWeofEtbC/h1TRbHTruXZ9imj8UukAcv86yIbxmO4E7ShUgjvmn3niDx7aQxBbvwnFAYyBJceKJwVcEA5Y3R3AggjupdQScZYAwL/wCIHjbT7EnXNZ094xKqAWV7LasWGDzv2YDAN/EM4PHWnQeO/G72MGot9mgV5/NhCa3IsUsKttZjcS3EkC4ZkTyyMlmB6DBxfEGseOdVWW1n8Q+Gk09leOayHjAMs6En5XLXJbpgHBUEDkcnM/hzWtbsZbf7bL4OeKNVVhH4rgR3VVCgeZ57EHbuBOD1zg8igDp0+IPxLeCRLa2uoppdwtvP17Siin+AkNAGdOQc7huB+VhxXPaj+0D8R9Clme4g8OXlvvYKBLFdmMbsAO1vKB2wCQAea6Ftaaa1I0bUPCmj3EwXYtz40iuY4GB+ZmVEzITwQMkBgpIYZWvLPFfhca7fyzDxx4VMHmYSPzbiaZmJPzSvHaKZpGLHMjDc3cnHAB19j+1b4qWcfbtF0SWHAyIUljYHPJ5kbt2/XtWlf/tAeDtdMd34q+HNhqNwUMfnSCCaQEEcAOpYLgk9fz6jzHTfh5axwXAfXvDt7PIEEbsmpbYgHBLbVtRnO0qSTgKW4zhls2fwXvZ7Nrg6u5QIWDxaDqrpnry32UYGMHP6UAeu2PxZ+GlrPNJpEI09pF2k/wBoahbK3flYYmA59M9as3XxI8J6rE09vq12uGxI1j4wvoJYx1ykV0sUb88V4zF8E9WmjWSDUGkjboy6FqxBHsRaU2b4I+IAp+zyTTv12jRdTTI+r2oGaAPbrPxvpAEkVh4s8bquCxDa7ocxA25J3SyswAHv+tU5/i1psciWOn/EbxZa3CA4F3pVjqAf0IaFPmHc/MTjuteSaZ8BvFF9dCLy7iNcfefT7iPnjjMiKO/rW+v7Mvik3Eil28hVyrhIcu2TwF87gYwckjk4x3oA9o0Hxl4gjheS58WXd1vVXVbzwBfZRSCQwMLqMNzjJPSrVt8YLWznli1LxL4buHUqVSSxvdNkwRnOxxISCMYI4614Gn7N3jBrNna0ukufMwsR+y7dm/G4sLjg7PmwAeeM/wAVXJv2aPEqo72j3hf5PLWaK2j74fcVuW24GSMbs8A7ewB9FL8SbiexF5YN4Ju7dioTZ4o2u5b7qgNbgBiQRtJHSmWnxF8RyzFX8EJcqAWI03XrS5kwATkIShOccAZr5stf2b/iC7iG4S3is92G23SMduc8LuAz1wM9ccgci7D+yv42ktw76joEUrYIR7iX5RzkHERGenTI680AfTc3j+8hmghk8BeMvMnj8yMJb2zrj0ZlnKof9lyp9BUsPxEs2jja58P+LrZmGdj6FcyFfYmNWH618z2v7KXi5iftetaDENw/1bzPxzk8xrz049z0xzv6H+zF4o0m/F3p/jePTrhFISeySVJADwRkMpAx70Ae93/xM8MacivqdxqVgrAkNeaReQDjry8QqWD4meBp4g6eMPD6g9pNQiRvxDMCK8rj+B3jsxKZPjN4iWTHKr55AP1+0D+Vadt8JPiBbqBH8Y9WIAI/eafvPJz/ABTH/PHSgD0+Pxr4VljSSPxLojo/Kst/EQ30O72q6mv6O5ITVtPYjqBcof615fbfC7x2jF7j4u6vIw+5s09FA9cguQe36+tXX+HHjGfzDd/Eu4ldyv7xdDtFfAOSN2Cfbrx7jigD0EeI9EwD/bOm4PQ/ak5/Wuc1r4reAtEtmmvPFWklFbDLazC5cHPdItzdc9ux9DXDah+z5DrNilj4g8ceKb+wi+aG285FiR+fm2FSv8TdgcHGcVSt/wBljwXGgWXVfEUgzll+0QqrEZxx5Xv60Aed/Fz4x6p8UdQj8E/DezvDaXkzQNIvyy368cYIHlx8MxLHleW2gMK+ofAHhi08G+D9L0KwjVY7SFVdlyfMkPLuSe7Nk/jgYHFUPh58OPDPw/tJIvDdh5U0wAmupWMk0uOxY9B7DA74zXYUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBFcW8Nymy4ijlTOdrqGGfoazLjwt4fuZxPcaFpU0wORJJaRswOMdSM9OK2KKAOfbwV4Vbdu8NaIdx3Nmwi5Pqfl9z+dRHwD4ObIbwn4fIPJzpsP8A8TXS0UAc9b+CPClsGFv4Y0OINjcE0+Jc46ZwvualPhHw2Qo/4R/SML93/Qo+Pp8vFblFAGDJ4N8NSKFfQdMKhiwH2ZOCQAT09AKg/wCEE8M7mI0iBcgjClgACMcAHA/CulooA5ufwP4cmkMj6XEGPUo7p/IilTwR4bSNEGj2pCKVBYFjg9eScmujooA57/hCvDeGA0azAbBICenSmv4H8NPtD6NasBzhlJHryM4NdHRQBzkfgfwvHK0iaBp25hg5gUgcY4HQfhU6eEPDaAY0DSjgEZa0QnB9yK3KKAOYm+H3gyd983hHw9I+ANz6bCTgduVoPw98FmTzD4Q8Ol/7x0yHP57a6eigDmk8BeD4wAnhTw+oBBGNOhGCOh+7Uq+CvCq42+GdEGDkYsIuD/3zXQUUAYsXhTw7CQYdB0mMg5BWzjGDjHp6cVpw2ltBK0kFvDHIwCsyIASB0BI7Cp6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAPtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Bonney tissue forceps have horizontal serration and sharp teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_16_271=[""].join("\n");
var outline_f0_16_271=null;
